id	sid	tid	token	lemma	pos
hls-11229	1	1	hrev_master	hrev_master	NOUN
hls-11229	2	1	[	[	X
hls-11229	2	2	page	page	NOUN
hls-11229	2	3	26	26	NUM
hls-11229	2	4	]	]	PUNCT
hls-11229	3	1	[	[	X
hls-11229	3	2	healthcare	healthcare	NOUN
hls-11229	3	3	in	in	ADP
hls-11229	3	4	low	low	ADJ
hls-11229	3	5	-	-	PUNCT
hls-11229	3	6	resource	resource	NOUN
hls-11229	3	7	settings	setting	NOUN
hls-11229	3	8	2023	2023	NUM
hls-11229	3	9	;	;	PUNCT
hls-11229	3	10	11:11229	11:11229	NUM
hls-11229	3	11	]	]	X
hls-11229	3	12	prevalence	prevalence	NOUN
hls-11229	3	13	of	of	ADP
hls-11229	3	14	mlsb	mlsb	PROPN
hls-11229	3	15	phenotypes	phenotype	NOUN
hls-11229	3	16	of	of	ADP
hls-11229	3	17	staphylococcus	staphylococcus	NOUN
hls-11229	3	18	aureus	aureus	NOUN
hls-11229	3	19	isolates	isolate	NOUN
hls-11229	3	20	in	in	ADP
hls-11229	3	21	a	a	DET
hls-11229	3	22	tertiary	tertiary	ADJ
hls-11229	3	23	care	care	NOUN
hls-11229	3	24	hospital	hospital	NOUN
hls-11229	3	25	of	of	ADP
hls-11229	3	26	delhi	delhi	PROPN
hls-11229	3	27	malika	malika	PROPN
hls-11229	3	28	grover	grover	PROPN
hls-11229	3	29	,	,	PUNCT
hls-11229	3	30	nisha	nisha	PROPN
hls-11229	3	31	goyal	goyal	PROPN
hls-11229	3	32	,	,	PUNCT
hls-11229	3	33	seema	seema	PROPN
hls-11229	3	34	gangar	gangar	PROPN
hls-11229	3	35	,	,	PUNCT
hls-11229	3	36	narendra	narendra	PROPN
hls-11229	3	37	pal	pal	PROPN
hls-11229	3	38	singh	singh	PROPN
hls-11229	3	39	department	department	PROPN
hls-11229	3	40	of	of	ADP
hls-11229	3	41	microbiology	microbiology	NOUN
hls-11229	3	42	,	,	PUNCT
hls-11229	3	43	university	university	NOUN
hls-11229	3	44	college	college	NOUN
hls-11229	3	45	of	of	ADP
hls-11229	3	46	medical	medical	PROPN
hls-11229	3	47	sciences	sciences	PROPN
hls-11229	3	48	&	&	CCONJ
hls-11229	3	49	guru	guru	PROPN
hls-11229	3	50	teg	teg	PROPN
hls-11229	3	51	bahadur	bahadur	PROPN
hls-11229	3	52	hospital	hospital	PROPN
hls-11229	3	53	,	,	PUNCT
hls-11229	3	54	delhi	delhi	PROPN
hls-11229	3	55	,	,	PUNCT
hls-11229	3	56	india	india	PROPN
hls-11229	3	57	abstract	abstract	NOUN
hls-11229	3	58	against	against	ADP
hls-11229	3	59	the	the	DET
hls-11229	3	60	backdrop	backdrop	NOUN
hls-11229	3	61	of	of	ADP
hls-11229	3	62	the	the	DET
hls-11229	3	63	ever	ever	ADV
hls-11229	3	64	-	-	PUNCT
hls-11229	3	65	changing	change	VERB
hls-11229	3	66	staphylococcal	staphylococcal	ADJ
hls-11229	3	67	resistance	resistance	NOUN
hls-11229	3	68	pattern	pattern	NOUN
hls-11229	3	69	,	,	PUNCT
hls-11229	3	70	clindamycin	clindamycin	NOUN
hls-11229	3	71	remains	remain	VERB
hls-11229	3	72	a	a	DET
hls-11229	3	73	viable	viable	ADJ
hls-11229	3	74	therapeutic	therapeutic	ADJ
hls-11229	3	75	alternative	alternative	ADJ
hls-11229	3	76	variation	variation	NOUN
hls-11229	3	77	of	of	ADP
hls-11229	3	78	clindamycin	clindamycin	NOUN
hls-11229	3	79	drug	drug	NOUN
hls-11229	3	80	resistance	resistance	NOUN
hls-11229	3	81	patterns	pattern	NOUN
hls-11229	3	82	with	with	ADP
hls-11229	3	83	geographic	geographic	ADJ
hls-11229	3	84	area	area	NOUN
hls-11229	3	85	make	make	VERB
hls-11229	3	86	inducible	inducible	ADJ
hls-11229	3	87	clindamycin	clindamycin	NOUN
hls-11229	3	88	resistance	resistance	NOUN
hls-11229	3	89	testing	testing	NOUN
hls-11229	3	90	imperative	imperative	NOUN
hls-11229	3	91	for	for	ADP
hls-11229	3	92	all	all	DET
hls-11229	3	93	staphylococcal	staphylococcal	ADJ
hls-11229	3	94	isolates	isolate	NOUN
hls-11229	3	95	to	to	PART
hls-11229	3	96	avoid	avoid	VERB
hls-11229	3	97	therapeutic	therapeutic	ADJ
hls-11229	3	98	failure	failure	NOUN
hls-11229	3	99	.	.	PUNCT
hls-11229	4	1	this	this	PRON
hls-11229	4	2	was	be	AUX
hls-11229	4	3	a	a	DET
hls-11229	4	4	prospective	prospective	ADJ
hls-11229	4	5	study	study	NOUN
hls-11229	4	6	conducted	conduct	VERB
hls-11229	4	7	over	over	ADP
hls-11229	4	8	a	a	DET
hls-11229	4	9	period	period	NOUN
hls-11229	4	10	of	of	ADP
hls-11229	4	11	1.5	1.5	NUM
hls-11229	4	12	years	year	NOUN
hls-11229	4	13	from	from	ADP
hls-11229	4	14	january	january	PROPN
hls-11229	4	15	2021	2021	NUM
hls-11229	4	16	until	until	ADP
hls-11229	4	17	june	june	PROPN
hls-11229	4	18	2022	2022	NUM
hls-11229	4	19	.	.	PUNCT
hls-11229	5	1	prevalence	prevalence	NOUN
hls-11229	5	2	of	of	ADP
hls-11229	5	3	different	different	ADJ
hls-11229	5	4	mlsb	mlsb	NOUN
hls-11229	5	5	phenotypes	phenotype	NOUN
hls-11229	5	6	of	of	ADP
hls-11229	5	7	staphylococcus	staphylococcus	NOUN
hls-11229	5	8	aureus	aureus	NOUN
hls-11229	5	9	isolates	isolate	NOUN
hls-11229	5	10	was	be	AUX
hls-11229	5	11	determined	determine	VERB
hls-11229	5	12	by	by	ADP
hls-11229	5	13	standard	standard	ADJ
hls-11229	5	14	disc	disc	NOUN
hls-11229	5	15	diffusion	diffusion	NOUN
hls-11229	5	16	method	method	NOUN
hls-11229	5	17	as	as	ADP
hls-11229	5	18	per	per	ADP
hls-11229	5	19	clsi	clsi	NOUN
hls-11229	5	20	guidelines	guideline	NOUN
hls-11229	5	21	.	.	PUNCT
hls-11229	6	1	pyogenic	pyogenic	ADJ
hls-11229	6	2	samples	sample	NOUN
hls-11229	6	3	received	receive	VERB
hls-11229	6	4	in	in	ADP
hls-11229	6	5	the	the	DET
hls-11229	6	6	microbiology	microbiology	NOUN
hls-11229	6	7	lab	lab	NOUN
hls-11229	6	8	that	that	PRON
hls-11229	6	9	yielded	yield	VERB
hls-11229	6	10	staphylococcus	staphylococcus	NOUN
hls-11229	6	11	aureus	aureus	NOUN
hls-11229	6	12	were	be	AUX
hls-11229	6	13	further	far	ADV
hls-11229	6	14	tested	test	VERB
hls-11229	6	15	for	for	ADP
hls-11229	6	16	the	the	DET
hls-11229	6	17	presence	presence	NOUN
hls-11229	6	18	of	of	ADP
hls-11229	6	19	clindamycin	clindamycin	NOUN
hls-11229	6	20	resistance	resistance	NOUN
hls-11229	6	21	by	by	ADP
hls-11229	6	22	disc	disc	NOUN
hls-11229	6	23	diffusion	diffusion	NOUN
hls-11229	6	24	method	method	NOUN
hls-11229	6	25	.	.	PUNCT
hls-11229	7	1	out	out	ADP
hls-11229	7	2	of	of	ADP
hls-11229	7	3	6586	6586	NUM
hls-11229	7	4	total	total	ADJ
hls-11229	7	5	pyogenic	pyogenic	ADJ
hls-11229	7	6	and	and	CCONJ
hls-11229	7	7	respiratory	respiratory	ADJ
hls-11229	7	8	specimens	specimen	NOUN
hls-11229	7	9	received	receive	VERB
hls-11229	7	10	in	in	ADP
hls-11229	7	11	the	the	DET
hls-11229	7	12	lab	lab	NOUN
hls-11229	7	13	,	,	PUNCT
hls-11229	7	14	staphylococcus	staphylococcus	NOUN
hls-11229	7	15	aureus	aureus	PROPN
hls-11229	7	16	was	be	AUX
hls-11229	7	17	yielded	yield	VERB
hls-11229	7	18	in	in	ADP
hls-11229	7	19	752	752	NUM
hls-11229	7	20	samples	sample	NOUN
hls-11229	7	21	.	.	PUNCT
hls-11229	8	1	on	on	ADP
hls-11229	8	2	further	further	ADJ
hls-11229	8	3	testing	testing	NOUN
hls-11229	8	4	for	for	ADP
hls-11229	8	5	the	the	DET
hls-11229	8	6	mlsb	mlsb	PROPN
hls-11229	8	7	phenotypes	phenotype	NOUN
hls-11229	8	8	,	,	PUNCT
hls-11229	8	9	16.3	16.3	NUM
hls-11229	8	10	%	%	NOUN
hls-11229	8	11	isolates	isolate	NOUN
hls-11229	8	12	were	be	AUX
hls-11229	8	13	found	find	VERB
hls-11229	8	14	to	to	PART
hls-11229	8	15	be	be	AUX
hls-11229	8	16	imlsb	imlsb	NOUN
hls-11229	8	17	,	,	PUNCT
hls-11229	8	18	19.28	19.28	NUM
hls-11229	8	19	%	%	NOUN
hls-11229	8	20	were	be	AUX
hls-11229	8	21	cmlsb	cmlsb	NOUN
hls-11229	8	22	,	,	PUNCT
hls-11229	8	23	43.1	43.1	NUM
hls-11229	8	24	%	%	NOUN
hls-11229	8	25	were	be	AUX
hls-11229	8	26	of	of	ADP
hls-11229	8	27	msb	msb	PROPN
hls-11229	8	28	type	type	PROPN
hls-11229	8	29	.	.	PUNCT
hls-11229	9	1	icr	icr	PROPN
hls-11229	9	2	screening	screening	NOUN
hls-11229	9	3	will	will	AUX
hls-11229	9	4	reduce	reduce	VERB
hls-11229	9	5	the	the	DET
hls-11229	9	6	unessential	unessential	ADJ
hls-11229	9	7	subjection	subjection	NOUN
hls-11229	9	8	of	of	ADP
hls-11229	9	9	the	the	DET
hls-11229	9	10	patient	patient	NOUN
hls-11229	9	11	to	to	ADP
hls-11229	9	12	the	the	DET
hls-11229	9	13	antibiotic	antibiotic	NOUN
hls-11229	9	14	,	,	PUNCT
hls-11229	9	15	and	and	CCONJ
hls-11229	9	16	would	would	AUX
hls-11229	9	17	prevent	prevent	VERB
hls-11229	9	18	unnecessary	unnecessary	ADJ
hls-11229	9	19	adverse	adverse	ADJ
hls-11229	9	20	effects	effect	NOUN
hls-11229	9	21	in	in	ADP
hls-11229	9	22	the	the	DET
hls-11229	9	23	patients	patient	NOUN
hls-11229	9	24	.	.	PUNCT
hls-11229	10	1	introduction	introduction	NOUN
hls-11229	10	2	staphylococcus	staphylococcus	NOUN
hls-11229	10	3	aureus	aureus	PROPN
hls-11229	10	4	(	(	PUNCT
hls-11229	10	5	s.	s.	PROPN
hls-11229	10	6	aureus	aureus	PROPN
hls-11229	10	7	)	)	PUNCT
hls-11229	10	8	is	be	AUX
hls-11229	10	9	a	a	DET
hls-11229	10	10	potential	potential	ADJ
hls-11229	10	11	pathogen	pathogen	NOUN
hls-11229	10	12	as	as	ADV
hls-11229	10	13	well	well	ADV
hls-11229	10	14	as	as	ADP
hls-11229	10	15	a	a	DET
hls-11229	10	16	colonizer	colonizer	NOUN
hls-11229	10	17	of	of	ADP
hls-11229	10	18	the	the	DET
hls-11229	10	19	humans	human	NOUN
hls-11229	10	20	owing	owe	VERB
hls-11229	10	21	to	to	ADP
hls-11229	10	22	the	the	DET
hls-11229	10	23	arsenal	arsenal	NOUN
hls-11229	10	24	of	of	ADP
hls-11229	10	25	virulence	virulence	NOUN
hls-11229	10	26	factors	factor	NOUN
hls-11229	10	27	including	include	VERB
hls-11229	10	28	toxins	toxin	NOUN
hls-11229	10	29	such	such	ADJ
hls-11229	10	30	as	as	ADP
hls-11229	10	31	tsst-1	tsst-1	NUM
hls-11229	10	32	(	(	PUNCT
hls-11229	10	33	toxic	toxic	ADJ
hls-11229	10	34	shock	shock	NOUN
hls-11229	10	35	syndrome	syndrome	NOUN
hls-11229	10	36	toxin	toxin	NOUN
hls-11229	10	37	)	)	PUNCT
hls-11229	10	38	,	,	PUNCT
hls-11229	10	39	exfoliative	exfoliative	ADJ
hls-11229	10	40	toxins	toxin	NOUN
hls-11229	10	41	(	(	PUNCT
hls-11229	10	42	eta	eta	INTJ
hls-11229	10	43	and	and	CCONJ
hls-11229	10	44	etb	etb	PROPN
hls-11229	10	45	)	)	PUNCT
hls-11229	10	46	,	,	PUNCT
hls-11229	10	47	heat	heat	NOUN
hls-11229	10	48	stable	stable	ADJ
hls-11229	10	49	enterotoxins	enterotoxin	NOUN
hls-11229	10	50	etc	etc	X
hls-11229	10	51	.	.	X
hls-11229	10	52	manifestation	manifestation	NOUN
hls-11229	10	53	of	of	ADP
hls-11229	10	54	staphylococcal	staphylococcal	ADJ
hls-11229	10	55	infections	infection	NOUN
hls-11229	10	56	ranges	range	VERB
hls-11229	10	57	from	from	ADP
hls-11229	10	58	local	local	ADJ
hls-11229	10	59	(	(	PUNCT
hls-11229	10	60	folliculitis	folliculitis	NOUN
hls-11229	10	61	,	,	PUNCT
hls-11229	10	62	carbuncles	carbuncle	NOUN
hls-11229	10	63	,	,	PUNCT
hls-11229	10	64	furuncles	furuncle	NOUN
hls-11229	10	65	,	,	PUNCT
hls-11229	10	66	impetigo	impetigo	NOUN
hls-11229	10	67	,	,	PUNCT
hls-11229	10	68	wound	wound	NOUN
hls-11229	10	69	infections	infection	NOUN
hls-11229	10	70	)	)	PUNCT
hls-11229	10	71	to	to	ADP
hls-11229	10	72	systemic	systemic	ADJ
hls-11229	10	73	(	(	PUNCT
hls-11229	10	74	endocarditis	endocarditis	NOUN
hls-11229	10	75	,	,	PUNCT
hls-11229	10	76	pneumonia	pneumonia	NOUN
hls-11229	10	77	,	,	PUNCT
hls-11229	10	78	sepsis	sepsis	NOUN
hls-11229	10	79	,	,	PUNCT
hls-11229	10	80	osteomyelitis	osteomyelitis	NOUN
hls-11229	10	81	,	,	PUNCT
hls-11229	10	82	arthritis	arthritis	NOUN
hls-11229	10	83	)	)	PUNCT
hls-11229	10	84	.	.	PUNCT
hls-11229	11	1	localised	localise	VERB
hls-11229	11	2	s.	s.	PROPN
hls-11229	11	3	aureus	aureus	PROPN
hls-11229	11	4	infections	infection	NOUN
hls-11229	11	5	have	have	VERB
hls-11229	11	6	the	the	DET
hls-11229	11	7	potential	potential	NOUN
hls-11229	11	8	to	to	PART
hls-11229	11	9	become	become	VERB
hls-11229	11	10	invasive	invasive	ADJ
hls-11229	11	11	and	and	CCONJ
hls-11229	11	12	cause	cause	VERB
hls-11229	11	13	bacteremia	bacteremia	NOUN
hls-11229	11	14	at	at	ADP
hls-11229	11	15	any	any	DET
hls-11229	11	16	stage	stage	NOUN
hls-11229	11	17	of	of	ADP
hls-11229	11	18	the	the	DET
hls-11229	11	19	infection	infection	NOUN
hls-11229	11	20	.	.	PUNCT
hls-11229	12	1	the	the	DET
hls-11229	12	2	mainstay	mainstay	NOUN
hls-11229	12	3	of	of	ADP
hls-11229	12	4	treatment	treatment	NOUN
hls-11229	12	5	for	for	ADP
hls-11229	12	6	these	these	DET
hls-11229	12	7	infections	infection	NOUN
hls-11229	12	8	include	include	VERB
hls-11229	12	9	cell	cell	NOUN
hls-11229	12	10	wall	wall	NOUN
hls-11229	12	11	inhibitors	inhibitor	NOUN
hls-11229	12	12	such	such	ADJ
hls-11229	12	13	as	as	ADP
hls-11229	12	14	β	β	NOUN
hls-11229	12	15	-	-	NOUN
hls-11229	12	16	lactams	lactam	NOUN
hls-11229	12	17	,	,	PUNCT
hls-11229	12	18	glycopeptides	glycopeptide	NOUN
hls-11229	12	19	,	,	PUNCT
hls-11229	12	20	dna	dna	NOUN
hls-11229	12	21	gyraseinhibiting	gyraseinhibite	VERB
hls-11229	12	22	quinolones	quinolone	NOUN
hls-11229	12	23	,	,	PUNCT
hls-11229	12	24	and	and	CCONJ
hls-11229	12	25	ribosomal	ribosomal	NOUN
hls-11229	12	26	inhibitors	inhibitor	NOUN
hls-11229	12	27	such	such	ADJ
hls-11229	12	28	as	as	ADP
hls-11229	12	29	macrolides	macrolide	NOUN
hls-11229	12	30	,	,	PUNCT
hls-11229	12	31	lincosamides	lincosamide	NOUN
hls-11229	12	32	and	and	CCONJ
hls-11229	12	33	streptogramins	streptogramin	NOUN
hls-11229	12	34	(	(	PUNCT
hls-11229	12	35	mlsb	mlsb	PROPN
hls-11229	12	36	)	)	PUNCT
hls-11229	12	37	.	.	PUNCT
hls-11229	13	1	mlsb	mlsb	PROPN
hls-11229	13	2	drugs	drug	NOUN
hls-11229	13	3	are	be	AUX
hls-11229	13	4	a	a	DET
hls-11229	13	5	good	good	ADJ
hls-11229	13	6	alternative	alternative	NOUN
hls-11229	13	7	in	in	ADP
hls-11229	13	8	treating	treat	VERB
hls-11229	13	9	infections	infection	NOUN
hls-11229	13	10	,	,	PUNCT
hls-11229	13	11	especially	especially	ADV
hls-11229	13	12	in	in	ADP
hls-11229	13	13	current	current	ADJ
hls-11229	13	14	times	time	NOUN
hls-11229	13	15	of	of	ADP
hls-11229	13	16	increasing	increase	VERB
hls-11229	13	17	resistance	resistance	NOUN
hls-11229	13	18	.	.	PUNCT
hls-11229	14	1	clindamycin	clindamycin	NOUN
hls-11229	14	2	in	in	ADP
hls-11229	14	3	particular	particular	ADJ
hls-11229	14	4	is	be	AUX
hls-11229	14	5	an	an	DET
hls-11229	14	6	important	important	ADJ
hls-11229	14	7	antibiotic	antibiotic	NOUN
hls-11229	14	8	for	for	ADP
hls-11229	14	9	skin	skin	NOUN
hls-11229	14	10	and	and	CCONJ
hls-11229	14	11	soft	soft	ADJ
hls-11229	14	12	tissue	tissue	NOUN
hls-11229	14	13	infections	infection	NOUN
hls-11229	14	14	caused	cause	VERB
hls-11229	14	15	by	by	ADP
hls-11229	14	16	s.	s.	PROPN
hls-11229	14	17	aureus	aureus	PROPN
hls-11229	14	18	(	(	PUNCT
hls-11229	14	19	especially	especially	ADV
hls-11229	14	20	mrsa	mrsa	NOUN
hls-11229	14	21	i.e.	i.e.	X
hls-11229	14	22	,	,	PUNCT
hls-11229	14	23	methicillin	methicillin	NOUN
hls-11229	14	24	resistant	resistant	ADJ
hls-11229	14	25	staphylococcus	staphylococcus	NOUN
hls-11229	14	26	aureus	aureus	NOUN
hls-11229	14	27	)	)	PUNCT
hls-11229	14	28	due	due	ADP
hls-11229	14	29	to	to	ADP
hls-11229	14	30	its	its	PRON
hls-11229	14	31	ease	ease	NOUN
hls-11229	14	32	of	of	ADP
hls-11229	14	33	administration	administration	NOUN
hls-11229	14	34	(	(	PUNCT
hls-11229	14	35	available	available	ADJ
hls-11229	14	36	as	as	ADP
hls-11229	14	37	oral	oral	ADJ
hls-11229	14	38	/	/	SYM
hls-11229	14	39	parenteral	parenteral	ADJ
hls-11229	14	40	)	)	PUNCT
hls-11229	14	41	and	and	CCONJ
hls-11229	14	42	its	its	PRON
hls-11229	14	43	property	property	NOUN
hls-11229	14	44	to	to	PART
hls-11229	14	45	neutralise	neutralise	VERB
hls-11229	14	46	toxins	toxin	NOUN
hls-11229	14	47	.	.	PUNCT
hls-11229	15	1	it	it	PRON
hls-11229	15	2	switches	switch	VERB
hls-11229	15	3	off	off	ADP
hls-11229	15	4	production	production	NOUN
hls-11229	15	5	of	of	ADP
hls-11229	15	6	toxins	toxin	NOUN
hls-11229	15	7	like	like	ADP
hls-11229	15	8	tsst	tsst	NOUN
hls-11229	15	9	responsible	responsible	ADJ
hls-11229	15	10	for	for	ADP
hls-11229	15	11	toxic	toxic	ADJ
hls-11229	15	12	shock	shock	NOUN
hls-11229	15	13	syndrome,1	syndrome,1	NOUN
hls-11229	15	14	alpha	alpha	NOUN
hls-11229	15	15	toxin	toxin	NOUN
hls-11229	15	16	which	which	PRON
hls-11229	15	17	is	be	AUX
hls-11229	15	18	a	a	DET
hls-11229	15	19	pore	pore	ADJ
hls-11229	15	20	forming	form	VERB
hls-11229	15	21	cytotoxin	cytotoxin	NOUN
hls-11229	15	22	leading	lead	VERB
hls-11229	15	23	to	to	ADP
hls-11229	15	24	infections	infection	NOUN
hls-11229	15	25	such	such	ADJ
hls-11229	15	26	as	as	ADP
hls-11229	15	27	dermonecrosis	dermonecrosis	NOUN
hls-11229	15	28	,	,	PUNCT
hls-11229	15	29	keratoconjuctivitis	keratoconjuctivitis	NOUN
hls-11229	15	30	and	and	CCONJ
hls-11229	15	31	pneumonia2	pneumonia2	PROPN
hls-11229	15	32	and	and	CCONJ
hls-11229	15	33	pvl	pvl	PROPN
hls-11229	15	34	(	(	PUNCT
hls-11229	15	35	panton	panton	PROPN
hls-11229	15	36	-	-	PUNCT
hls-11229	15	37	valentine	valentine	PROPN
hls-11229	15	38	leukocidin	leukocidin	ADV
hls-11229	15	39	)	)	PUNCT
hls-11229	15	40	,	,	PUNCT
hls-11229	15	41	which	which	PRON
hls-11229	15	42	is	be	AUX
hls-11229	15	43	associated	associate	VERB
hls-11229	15	44	with	with	ADP
hls-11229	15	45	manifestations	manifestation	NOUN
hls-11229	15	46	like	like	ADP
hls-11229	15	47	necrotising	necrotise	VERB
hls-11229	15	48	pneumonia	pneumonia	NOUN
hls-11229	15	49	,	,	PUNCT
hls-11229	15	50	purpura	purpura	NOUN
hls-11229	15	51	fulminans	fulminan	NOUN
hls-11229	15	52	and	and	CCONJ
hls-11229	15	53	skin	skin	NOUN
hls-11229	15	54	sepsis.3	sepsis.3	PROPN
hls-11229	15	55	the	the	DET
hls-11229	15	56	three	three	NUM
hls-11229	15	57	antimicrobial	antimicrobial	ADJ
hls-11229	15	58	classes	class	NOUN
hls-11229	15	59	of	of	ADP
hls-11229	15	60	mlsb	mlsb	PROPN
hls-11229	15	61	act	act	VERB
hls-11229	15	62	by	by	ADP
hls-11229	15	63	binding	bind	VERB
hls-11229	15	64	to	to	ADP
hls-11229	15	65	the	the	DET
hls-11229	15	66	50s	50	NOUN
hls-11229	15	67	ribosomal	ribosomal	NOUN
hls-11229	15	68	subunit	subunit	NOUN
hls-11229	15	69	,	,	PUNCT
hls-11229	15	70	thus	thus	ADV
hls-11229	15	71	inhibiting	inhibit	VERB
hls-11229	15	72	protein	protein	NOUN
hls-11229	15	73	synthesis	synthesis	NOUN
hls-11229	15	74	in	in	ADP
hls-11229	15	75	the	the	DET
hls-11229	15	76	bacteria.4	bacteria.4	PROPN
hls-11229	15	77	resistance	resistance	NOUN
hls-11229	15	78	amongst	amongst	ADP
hls-11229	15	79	these	these	PRON
hls-11229	15	80	can	can	AUX
hls-11229	15	81	be	be	AUX
hls-11229	15	82	conferred	confer	VERB
hls-11229	15	83	mainly	mainly	ADV
hls-11229	15	84	by	by	ADP
hls-11229	15	85	three	three	NUM
hls-11229	15	86	mechanisms	mechanism	NOUN
hls-11229	15	87	–	–	PUNCT
hls-11229	15	88	target	target	NOUN
hls-11229	15	89	site	site	NOUN
hls-11229	15	90	modification	modification	NOUN
hls-11229	15	91	,	,	PUNCT
hls-11229	15	92	antimicrobial	antimicrobial	ADJ
hls-11229	15	93	inactivation	inactivation	NOUN
hls-11229	15	94	and	and	CCONJ
hls-11229	15	95	efflux	efflux	NOUN
hls-11229	15	96	.	.	PUNCT
hls-11229	16	1	the	the	DET
hls-11229	16	2	enzyme	enzyme	NOUN
hls-11229	16	3	erythromycin	erythromycin	VERB
hls-11229	16	4	ribosome	ribosome	ADJ
hls-11229	16	5	methylases	methylase	NOUN
hls-11229	16	6	plays	play	VERB
hls-11229	16	7	the	the	DET
hls-11229	16	8	most	most	ADV
hls-11229	16	9	significant	significant	ADJ
hls-11229	16	10	role	role	NOUN
hls-11229	16	11	in	in	ADP
hls-11229	16	12	the	the	DET
hls-11229	16	13	resistance	resistance	NOUN
hls-11229	16	14	,	,	PUNCT
hls-11229	16	15	by	by	ADP
hls-11229	16	16	attaching	attach	VERB
hls-11229	16	17	the	the	DET
hls-11229	16	18	adenine	adenine	ADJ
hls-11229	16	19	residue	residue	NOUN
hls-11229	16	20	of	of	ADP
hls-11229	16	21	23s	23s	PROPN
hls-11229	16	22	rrna	rrna	PROPN
hls-11229	16	23	to	to	ADP
hls-11229	16	24	methyl	methyl	NOUN
hls-11229	16	25	groups	group	NOUN
hls-11229	16	26	,	,	PUNCT
hls-11229	16	27	thus	thus	ADV
hls-11229	16	28	decreasing	decrease	VERB
hls-11229	16	29	affinity	affinity	NOUN
hls-11229	16	30	for	for	ADP
hls-11229	16	31	mlsb	mlsb	NOUN
hls-11229	16	32	antibiotics	antibiotic	NOUN
hls-11229	16	33	.	.	PUNCT
hls-11229	17	1	it	it	PRON
hls-11229	17	2	is	be	AUX
hls-11229	17	3	encoded	encode	VERB
hls-11229	17	4	by	by	ADP
hls-11229	17	5	the	the	DET
hls-11229	17	6	erm	erm	PROPN
hls-11229	17	7	(	(	PUNCT
hls-11229	17	8	erythromycin	erythromycin	VERB
hls-11229	17	9	ribosome	ribosome	ADJ
hls-11229	17	10	methylation	methylation	NOUN
hls-11229	17	11	)	)	PUNCT
hls-11229	17	12	gene	gene	NOUN
hls-11229	17	13	which	which	PRON
hls-11229	17	14	is	be	AUX
hls-11229	17	15	of	of	ADP
hls-11229	17	16	three	three	NUM
hls-11229	17	17	main	main	ADJ
hls-11229	17	18	types	type	NOUN
hls-11229	18	1	i.e.	i.e.	X
hls-11229	18	2	,	,	PUNCT
hls-11229	18	3	erm	erm	PROPN
hls-11229	18	4	(	(	PUNCT
hls-11229	18	5	a	a	NOUN
hls-11229	18	6	)	)	PUNCT
hls-11229	18	7	,	,	PUNCT
hls-11229	18	8	erm	erm	PROPN
hls-11229	18	9	(	(	PUNCT
hls-11229	18	10	b	b	NOUN
hls-11229	18	11	)	)	PUNCT
hls-11229	18	12	and	and	CCONJ
hls-11229	18	13	erm	erm	INTJ
hls-11229	18	14	(	(	PUNCT
hls-11229	18	15	c	c	NOUN
hls-11229	18	16	)	)	PUNCT
hls-11229	18	17	;	;	PUNCT
hls-11229	18	18	also	also	ADV
hls-11229	18	19	,	,	PUNCT
hls-11229	18	20	genes	gene	NOUN
hls-11229	18	21	erm	erm	VERB
hls-11229	18	22	(	(	PUNCT
hls-11229	18	23	f	f	X
hls-11229	18	24	)	)	PUNCT
hls-11229	18	25	and	and	CCONJ
hls-11229	18	26	erm	erm	PROPN
hls-11229	18	27	(	(	PUNCT
hls-11229	18	28	y	y	NOUN
hls-11229	18	29	)	)	PUNCT
hls-11229	18	30	may	may	AUX
hls-11229	18	31	be	be	AUX
hls-11229	18	32	responsible	responsible	ADJ
hls-11229	18	33	.	.	PUNCT
hls-11229	19	1	the	the	DET
hls-11229	19	2	other	other	ADJ
hls-11229	19	3	mechanisms	mechanism	NOUN
hls-11229	19	4	that	that	PRON
hls-11229	19	5	contribute	contribute	VERB
hls-11229	19	6	to	to	ADP
hls-11229	19	7	the	the	DET
hls-11229	19	8	cross	cross	NOUN
hls-11229	19	9	resistance	resistance	NOUN
hls-11229	19	10	of	of	ADP
hls-11229	19	11	these	these	DET
hls-11229	19	12	mlsb	mlsb	NOUN
hls-11229	19	13	phenotypes	phenotype	NOUN
hls-11229	19	14	include	include	VERB
hls-11229	19	15	drug	drug	NOUN
hls-11229	19	16	inactivation	inactivation	NOUN
hls-11229	19	17	mediated	mediate	VERB
hls-11229	19	18	by	by	ADP
hls-11229	19	19	lun	lun	ADJ
hls-11229	19	20	gene	gene	NOUN
hls-11229	19	21	and	and	CCONJ
hls-11229	19	22	active	active	ADJ
hls-11229	19	23	efflux	efflux	NOUN
hls-11229	19	24	mechanisms	mechanism	NOUN
hls-11229	19	25	that	that	PRON
hls-11229	19	26	pumps	pump	VERB
hls-11229	19	27	out	out	ADP
hls-11229	19	28	antimicrobials	antimicrobial	NOUN
hls-11229	19	29	from	from	ADP
hls-11229	19	30	the	the	DET
hls-11229	19	31	bacteria	bacteria	NOUN
hls-11229	19	32	,	,	PUNCT
hls-11229	19	33	mediated	mediate	VERB
hls-11229	19	34	by	by	ADP
hls-11229	19	35	msr	msr	NOUN
hls-11229	19	36	gene.5	gene.5	VERB
hls-11229	19	37	mlsb	mlsb	NOUN
hls-11229	19	38	drugs	drug	NOUN
hls-11229	19	39	can	can	AUX
hls-11229	19	40	exist	exist	VERB
hls-11229	19	41	as	as	ADP
hls-11229	19	42	different	different	ADJ
hls-11229	19	43	phenotypes	phenotype	NOUN
hls-11229	19	44	–	–	PUNCT
hls-11229	19	45	constitutive	constitutive	ADJ
hls-11229	19	46	,	,	PUNCT
hls-11229	19	47	inducible	inducible	ADJ
hls-11229	19	48	,	,	PUNCT
hls-11229	19	49	or	or	CCONJ
hls-11229	19	50	msb	msb	PROPN
hls-11229	19	51	(	(	PUNCT
hls-11229	19	52	figure	figure	NOUN
hls-11229	19	53	1	1	NUM
hls-11229	19	54	):	):	PUNCT
hls-11229	19	55	i	i	PROPN
hls-11229	19	56	)	)	PUNCT
hls-11229	19	57	constitutive	constitutive	ADJ
hls-11229	19	58	mlsb	mlsb	NOUN
hls-11229	19	59	(	(	PUNCT
hls-11229	19	60	cmlsb	cmlsb	PROPN
hls-11229	19	61	)	)	PUNCT
hls-11229	19	62	–	–	PUNCT
hls-11229	19	63	defined	define	VERB
hls-11229	19	64	as	as	ADP
hls-11229	19	65	those	those	DET
hls-11229	19	66	isolates	isolate	NOUN
hls-11229	19	67	which	which	PRON
hls-11229	19	68	are	be	AUX
hls-11229	19	69	clindamycin	clindamycin	PRON
hls-11229	19	70	and	and	CCONJ
hls-11229	19	71	erythromycin	erythromycin	NOUN
hls-11229	19	72	resistant	resistant	ADJ
hls-11229	19	73	;	;	PUNCT
hls-11229	19	74	ii	ii	X
hls-11229	19	75	)	)	PUNCT
hls-11229	19	76	inducible	inducible	ADJ
hls-11229	19	77	mlsb	mlsb	NOUN
hls-11229	19	78	(	(	PUNCT
hls-11229	19	79	imlsb	imlsb	PROPN
hls-11229	19	80	)	)	PUNCT
hls-11229	19	81	–	–	PUNCT
hls-11229	19	82	defined	define	VERB
hls-11229	19	83	as	as	ADP
hls-11229	19	84	isolates	isolate	NOUN
hls-11229	19	85	which	which	PRON
hls-11229	19	86	are	be	AUX
hls-11229	19	87	clindamycin	clindamycin	NOUN
hls-11229	19	88	susceptible	susceptible	ADJ
hls-11229	19	89	and	and	CCONJ
hls-11229	19	90	erythromycin	erythromycin	NOUN
hls-11229	19	91	resistant	resistant	ADJ
hls-11229	19	92	.	.	PUNCT
hls-11229	20	1	however	however	ADV
hls-11229	20	2	,	,	PUNCT
hls-11229	20	3	a	a	DET
hls-11229	20	4	dshaped	dshape	VERB
hls-11229	20	5	zone	zone	NOUN
hls-11229	20	6	of	of	ADP
hls-11229	20	7	inhibition	inhibition	NOUN
hls-11229	20	8	is	be	AUX
hls-11229	20	9	seen	see	VERB
hls-11229	20	10	around	around	ADP
hls-11229	20	11	clindamycin	clindamycin	NOUN
hls-11229	20	12	,	,	PUNCT
hls-11229	20	13	with	with	ADP
hls-11229	20	14	flattening	flattening	NOUN
hls-11229	20	15	towards	towards	ADP
hls-11229	20	16	the	the	DET
hls-11229	20	17	erythromycin	erythromycin	NOUN
hls-11229	20	18	disc	disc	NOUN
hls-11229	20	19	;	;	PUNCT
hls-11229	20	20	iii	iii	X
hls-11229	20	21	)	)	PUNCT
hls-11229	20	22	msb	msb	PROPN
hls-11229	20	23	–	–	PUNCT
hls-11229	20	24	is	be	AUX
hls-11229	20	25	defined	define	VERB
hls-11229	20	26	as	as	ADP
hls-11229	20	27	those	those	DET
hls-11229	20	28	isolates	isolate	NOUN
hls-11229	20	29	which	which	PRON
hls-11229	20	30	are	be	AUX
hls-11229	20	31	clindamycin	clindamycin	NOUN
hls-11229	20	32	susceptible	susceptible	ADJ
hls-11229	20	33	and	and	CCONJ
hls-11229	20	34	erythromycin	erythromycin	NOUN
hls-11229	20	35	resistant	resistant	ADJ
hls-11229	20	36	with	with	ADP
hls-11229	20	37	a	a	DET
hls-11229	20	38	circular	circular	ADJ
hls-11229	20	39	zone	zone	NOUN
hls-11229	20	40	of	of	ADP
hls-11229	20	41	inhibition	inhibition	NOUN
hls-11229	20	42	around	around	ADP
hls-11229	20	43	the	the	DET
hls-11229	20	44	two	two	NUM
hls-11229	20	45	.	.	PUNCT
hls-11229	21	1	clinical	clinical	ADJ
hls-11229	21	2	and	and	CCONJ
hls-11229	21	3	laboratory	laboratory	NOUN
hls-11229	21	4	standards	standard	NOUN
hls-11229	21	5	institute	institute	PROPN
hls-11229	21	6	(	(	PUNCT
hls-11229	21	7	clsi	clsi	PROPN
hls-11229	21	8	)	)	PUNCT
hls-11229	21	9	states	state	VERB
hls-11229	21	10	two	two	NUM
hls-11229	21	11	methods	method	NOUN
hls-11229	21	12	for	for	ADP
hls-11229	21	13	detecting	detect	VERB
hls-11229	21	14	inducible	inducible	ADJ
hls-11229	21	15	clindamycin	clindamycin	NOUN
hls-11229	21	16	resistance	resistance	NOUN
hls-11229	21	17	(	(	PUNCT
hls-11229	21	18	icr	icr	PROPN
hls-11229	21	19	)	)	PUNCT
hls-11229	21	20	,	,	PUNCT
hls-11229	21	21	i.e.	i.e.	X
hls-11229	21	22	,	,	PUNCT
hls-11229	21	23	by	by	ADP
hls-11229	21	24	disc	disc	NOUN
hls-11229	21	25	diffusion	diffusion	NOUN
hls-11229	21	26	and	and	CCONJ
hls-11229	21	27	broth	broth	ADJ
hls-11229	21	28	microdilution	microdilution	NOUN
hls-11229	21	29	.	.	PUNCT
hls-11229	22	1	detection	detection	NOUN
hls-11229	22	2	of	of	ADP
hls-11229	22	3	inducible	inducible	ADJ
hls-11229	22	4	clindamycin	clindamycin	NOUN
hls-11229	22	5	resistance	resistance	NOUN
hls-11229	22	6	in	in	ADP
hls-11229	22	7	particular	particular	ADJ
hls-11229	22	8	holds	hold	VERB
hls-11229	22	9	significance	significance	NOUN
hls-11229	22	10	in	in	ADP
hls-11229	22	11	clinical	clinical	ADJ
hls-11229	22	12	scenarios	scenario	NOUN
hls-11229	22	13	,	,	PUNCT
hls-11229	22	14	wherein	wherein	SCONJ
hls-11229	22	15	the	the	DET
hls-11229	22	16	s.	s.	PROPN
hls-11229	22	17	aureus	aureus	PROPN
hls-11229	22	18	isolates	isolate	NOUN
hls-11229	22	19	exhibiting	exhibit	VERB
hls-11229	22	20	in	in	ADP
hls-11229	22	21	vitro	vitro	X
hls-11229	22	22	clindamycin	clindamycin	NOUN
hls-11229	22	23	susceptibility	susceptibility	NOUN
hls-11229	22	24	will	will	AUX
hls-11229	22	25	not	not	PART
hls-11229	22	26	show	show	VERB
hls-11229	22	27	in	in	ADP
hls-11229	22	28	vivo	vivo	ADJ
hls-11229	22	29	response	response	NOUN
hls-11229	22	30	on	on	ADP
hls-11229	22	31	administration	administration	NOUN
hls-11229	22	32	of	of	ADP
hls-11229	22	33	the	the	DET
hls-11229	22	34	drug	drug	NOUN
hls-11229	22	35	.	.	PUNCT
hls-11229	23	1	this	this	PRON
hls-11229	23	2	leads	lead	VERB
hls-11229	23	3	to	to	ADP
hls-11229	23	4	unnecessary	unnecessary	ADJ
hls-11229	23	5	overuse	overuse	NOUN
hls-11229	23	6	of	of	ADP
hls-11229	23	7	the	the	DET
hls-11229	23	8	drug	drug	NOUN
hls-11229	23	9	in	in	ADP
hls-11229	23	10	the	the	DET
hls-11229	23	11	patient	patient	NOUN
hls-11229	23	12	,	,	PUNCT
hls-11229	23	13	thus	thus	ADV
hls-11229	23	14	enhancing	enhance	VERB
hls-11229	23	15	the	the	DET
hls-11229	23	16	risk	risk	NOUN
hls-11229	23	17	of	of	ADP
hls-11229	23	18	emergence	emergence	NOUN
hls-11229	23	19	of	of	ADP
hls-11229	23	20	resistant	resistant	ADJ
hls-11229	23	21	strains	strain	NOUN
hls-11229	23	22	of	of	ADP
hls-11229	23	23	bacteria	bacteria	NOUN
hls-11229	23	24	and	and	CCONJ
hls-11229	23	25	putting	put	VERB
hls-11229	23	26	the	the	DET
hls-11229	23	27	patient	patient	NOUN
hls-11229	23	28	at	at	ADP
hls-11229	23	29	increased	increase	VERB
hls-11229	23	30	risk	risk	NOUN
hls-11229	23	31	of	of	ADP
hls-11229	23	32	side	side	NOUN
hls-11229	23	33	effects	effect	NOUN
hls-11229	23	34	of	of	ADP
hls-11229	23	35	the	the	DET
hls-11229	23	36	drug	drug	NOUN
hls-11229	23	37	.	.	PUNCT
hls-11229	24	1	improper	improper	ADJ
hls-11229	24	2	treatment	treatment	NOUN
hls-11229	24	3	during	during	ADP
hls-11229	24	4	the	the	DET
hls-11229	24	5	initial	initial	ADJ
hls-11229	24	6	phase	phase	NOUN
hls-11229	24	7	can	can	AUX
hls-11229	24	8	also	also	ADV
hls-11229	24	9	put	put	VERB
hls-11229	24	10	the	the	DET
hls-11229	24	11	patient	patient	NOUN
hls-11229	24	12	at	at	ADP
hls-11229	24	13	risk	risk	NOUN
hls-11229	24	14	for	for	ADP
hls-11229	24	15	metastasis	metastasis	NOUN
hls-11229	24	16	of	of	ADP
hls-11229	24	17	the	the	DET
hls-11229	24	18	disease	disease	NOUN
hls-11229	24	19	.	.	PUNCT
hls-11229	25	1	our	our	PRON
hls-11229	25	2	current	current	ADJ
hls-11229	25	3	study	study	NOUN
hls-11229	25	4	aims	aim	VERB
hls-11229	25	5	at	at	ADP
hls-11229	25	6	identifying	identify	VERB
hls-11229	25	7	the	the	DET
hls-11229	25	8	distribution	distribution	NOUN
hls-11229	25	9	of	of	ADP
hls-11229	25	10	mlsb	mlsb	NOUN
hls-11229	25	11	phenotypes	phenotype	NOUN
hls-11229	25	12	of	of	ADP
hls-11229	25	13	s.	s.	PROPN
hls-11229	25	14	aureus	aureus	PROPN
hls-11229	25	15	isolates	isolate	NOUN
hls-11229	25	16	for	for	ADP
hls-11229	25	17	better	well	ADJ
hls-11229	25	18	understanding	understanding	NOUN
hls-11229	25	19	of	of	ADP
hls-11229	25	20	healthcare	healthcare	NOUN
hls-11229	25	21	in	in	ADP
hls-11229	25	22	low	low	ADJ
hls-11229	25	23	-	-	PUNCT
hls-11229	25	24	resource	resource	NOUN
hls-11229	25	25	settings	setting	NOUN
hls-11229	25	26	2023	2023	NUM
hls-11229	25	27	;	;	PUNCT
hls-11229	25	28	volume	volume	NOUN
hls-11229	25	29	11:11229	11:11229	NUM
hls-11229	25	30	correspondence	correspondence	NOUN
hls-11229	25	31	:	:	PUNCT
hls-11229	25	32	nisha	nisha	PROPN
hls-11229	25	33	goyal	goyal	PROPN
hls-11229	25	34	,	,	PUNCT
hls-11229	25	35	department	department	NOUN
hls-11229	25	36	of	of	ADP
hls-11229	25	37	microbiology	microbiology	NOUN
hls-11229	25	38	,	,	PUNCT
hls-11229	25	39	university	university	NOUN
hls-11229	25	40	college	college	NOUN
hls-11229	25	41	of	of	ADP
hls-11229	25	42	medical	medical	PROPN
hls-11229	25	43	sciences	sciences	PROPN
hls-11229	25	44	&	&	CCONJ
hls-11229	25	45	guru	guru	PROPN
hls-11229	25	46	teg	teg	PROPN
hls-11229	25	47	bahadur	bahadur	PROPN
hls-11229	25	48	hospital	hospital	PROPN
hls-11229	25	49	,	,	PUNCT
hls-11229	25	50	110095	110095	NUM
hls-11229	25	51	delhi	delhi	PROPN
hls-11229	25	52	,	,	PUNCT
hls-11229	25	53	india	india	PROPN
hls-11229	25	54	.	.	PUNCT
hls-11229	26	1	tel	tel	PROPN
hls-11229	26	2	.	.	PUNCT
hls-11229	26	3	:	:	PUNCT
hls-11229	27	1	+91.8447444427	+91.8447444427	X
hls-11229	27	2	.	.	PUNCT
hls-11229	28	1	e	e	X
hls-11229	28	2	-	-	NOUN
hls-11229	28	3	mail	mail	NOUN
hls-11229	28	4	:	:	PUNCT
hls-11229	29	1	drnishagoyalucms@gmail.com	drnishagoyalucms@gmail.com	X
hls-11229	29	2	key	key	ADJ
hls-11229	29	3	words	word	NOUN
hls-11229	29	4	:	:	PUNCT
hls-11229	29	5	staphylococcus	staphylococcus	NOUN
hls-11229	29	6	aureus	aureus	NOUN
hls-11229	29	7	,	,	PUNCT
hls-11229	29	8	inducible	inducible	ADJ
hls-11229	29	9	clindamycin	clindamycin	NOUN
hls-11229	29	10	resistance	resistance	NOUN
hls-11229	29	11	,	,	PUNCT
hls-11229	29	12	constitutive	constitutive	ADJ
hls-11229	29	13	clindamycin	clindamycin	NOUN
hls-11229	29	14	resistance	resistance	NOUN
hls-11229	29	15	,	,	PUNCT
hls-11229	29	16	msb	msb	PROPN
hls-11229	29	17	phenotype	phenotype	NOUN
hls-11229	29	18	.	.	PUNCT
hls-11229	30	1	conflict	conflict	NOUN
hls-11229	30	2	of	of	ADP
hls-11229	30	3	interest	interest	NOUN
hls-11229	30	4	:	:	PUNCT
hls-11229	30	5	the	the	DET
hls-11229	30	6	authors	author	NOUN
hls-11229	30	7	declare	declare	VERB
hls-11229	30	8	no	no	DET
hls-11229	30	9	potential	potential	ADJ
hls-11229	30	10	conflict	conflict	NOUN
hls-11229	30	11	of	of	ADP
hls-11229	30	12	interest	interest	NOUN
hls-11229	30	13	,	,	PUNCT
hls-11229	30	14	and	and	CCONJ
hls-11229	30	15	all	all	DET
hls-11229	30	16	authors	author	NOUN
hls-11229	30	17	confirm	confirm	VERB
hls-11229	30	18	accuracy	accuracy	NOUN
hls-11229	30	19	.	.	PUNCT
hls-11229	31	1	ethics	ethic	NOUN
hls-11229	31	2	approval	approval	NOUN
hls-11229	31	3	and	and	CCONJ
hls-11229	31	4	consent	consent	NOUN
hls-11229	31	5	to	to	PART
hls-11229	31	6	participate	participate	VERB
hls-11229	31	7	:	:	PUNCT
hls-11229	31	8	not	not	PART
hls-11229	31	9	applicable	applicable	ADJ
hls-11229	31	10	.	.	PUNCT
hls-11229	32	1	this	this	DET
hls-11229	32	2	study	study	NOUN
hls-11229	32	3	used	use	VERB
hls-11229	32	4	only	only	ADV
hls-11229	32	5	the	the	DET
hls-11229	32	6	samples	sample	NOUN
hls-11229	32	7	received	receive	VERB
hls-11229	32	8	in	in	ADP
hls-11229	32	9	the	the	DET
hls-11229	32	10	lab	lab	NOUN
hls-11229	32	11	for	for	ADP
hls-11229	32	12	routine	routine	ADJ
hls-11229	32	13	susceptibility	susceptibility	NOUN
hls-11229	32	14	testing	testing	NOUN
hls-11229	32	15	and	and	CCONJ
hls-11229	32	16	no	no	DET
hls-11229	32	17	other	other	ADJ
hls-11229	32	18	sample	sample	NOUN
hls-11229	32	19	was	be	AUX
hls-11229	32	20	collected	collect	VERB
hls-11229	32	21	for	for	ADP
hls-11229	32	22	the	the	DET
hls-11229	32	23	purpose	purpose	NOUN
hls-11229	32	24	of	of	ADP
hls-11229	32	25	this	this	DET
hls-11229	32	26	study	study	NOUN
hls-11229	32	27	.	.	PUNCT
hls-11229	33	1	patients	patient	NOUN
hls-11229	33	2	were	be	AUX
hls-11229	33	3	not	not	PART
hls-11229	33	4	identified	identify	VERB
hls-11229	33	5	or	or	CCONJ
hls-11229	33	6	visited	visit	VERB
hls-11229	33	7	at	at	ADP
hls-11229	33	8	any	any	DET
hls-11229	33	9	point	point	NOUN
hls-11229	33	10	of	of	ADP
hls-11229	33	11	time	time	NOUN
hls-11229	33	12	.	.	PUNCT
hls-11229	34	1	informed	informed	ADJ
hls-11229	34	2	consent	consent	NOUN
hls-11229	34	3	:	:	PUNCT
hls-11229	34	4	not	not	PART
hls-11229	34	5	applicable	applicable	ADJ
hls-11229	34	6	patient	patient	ADJ
hls-11229	34	7	consent	consent	NOUN
hls-11229	34	8	for	for	ADP
hls-11229	34	9	publication	publication	NOUN
hls-11229	34	10	:	:	PUNCT
hls-11229	34	11	not	not	PART
hls-11229	34	12	applicable	applicable	ADJ
hls-11229	34	13	availability	availability	NOUN
hls-11229	34	14	of	of	ADP
hls-11229	34	15	data	datum	NOUN
hls-11229	34	16	and	and	CCONJ
hls-11229	34	17	materials	material	NOUN
hls-11229	34	18	:	:	PUNCT
hls-11229	34	19	all	all	DET
hls-11229	34	20	data	datum	NOUN
hls-11229	34	21	generated	generate	VERB
hls-11229	34	22	or	or	CCONJ
hls-11229	34	23	analyzed	analyze	VERB
hls-11229	34	24	during	during	ADP
hls-11229	34	25	this	this	DET
hls-11229	34	26	study	study	NOUN
hls-11229	34	27	are	be	AUX
hls-11229	34	28	included	include	VERB
hls-11229	34	29	in	in	ADP
hls-11229	34	30	this	this	DET
hls-11229	34	31	published	publish	VERB
hls-11229	34	32	article	article	NOUN
hls-11229	34	33	.	.	PUNCT
hls-11229	35	1	received	receive	VERB
hls-11229	35	2	for	for	ADP
hls-11229	35	3	publication	publication	NOUN
hls-11229	35	4	:	:	PUNCT
hls-11229	35	5	31	31	NUM
hls-11229	35	6	january	january	PROPN
hls-11229	35	7	2023	2023	NUM
hls-11229	35	8	.	.	PUNCT
hls-11229	36	1	accepted	accept	VERB
hls-11229	36	2	for	for	ADP
hls-11229	36	3	publication	publication	NOUN
hls-11229	36	4	:	:	PUNCT
hls-11229	36	5	7	7	NUM
hls-11229	36	6	june	june	PROPN
hls-11229	36	7	2023	2023	NUM
hls-11229	36	8	.	.	PUNCT
hls-11229	37	1	this	this	DET
hls-11229	37	2	work	work	NOUN
hls-11229	37	3	is	be	AUX
hls-11229	37	4	licensed	license	VERB
hls-11229	37	5	under	under	ADP
hls-11229	37	6	a	a	DET
hls-11229	37	7	creative	creative	ADJ
hls-11229	37	8	commons	common	NOUN
hls-11229	37	9	attribution	attribution	NOUN
hls-11229	37	10	4.0	4.0	NUM
hls-11229	37	11	license	license	NOUN
hls-11229	37	12	(	(	PUNCT
hls-11229	37	13	by	by	ADP
hls-11229	37	14	-	-	PUNCT
hls-11229	37	15	nc	nc	PROPN
hls-11229	37	16	4.0	4.0	NUM
hls-11229	37	17	)	)	PUNCT
hls-11229	37	18	.	.	PUNCT
hls-11229	38	1	©	©	PROPN
hls-11229	38	2	copyright	copyright	NOUN
hls-11229	38	3	:	:	PUNCT
hls-11229	38	4	the	the	DET
hls-11229	38	5	author(s	author(s	PROPN
hls-11229	38	6	)	)	PUNCT
hls-11229	38	7	,	,	PUNCT
hls-11229	38	8	2023	2023	NUM
hls-11229	38	9	licensee	licensee	NOUN
hls-11229	38	10	pagepress	pagepress	NOUN
hls-11229	38	11	,	,	PUNCT
hls-11229	38	12	italy	italy	PROPN
hls-11229	38	13	healthcare	healthcare	PROPN
hls-11229	38	14	in	in	ADP
hls-11229	38	15	low	low	ADJ
hls-11229	38	16	-	-	PUNCT
hls-11229	38	17	resource	resource	NOUN
hls-11229	38	18	settings	setting	NOUN
hls-11229	38	19	2023	2023	NUM
hls-11229	38	20	;	;	PUNCT
hls-11229	38	21	11:11229	11:11229	NUM
hls-11229	38	22	doi:10.4081	doi:10.4081	PROPN
hls-11229	38	23	/	/	SYM
hls-11229	38	24	hls.2023.11229	hls.2023.11229	PROPN
hls-11229	38	25	publisher	publisher	NOUN
hls-11229	38	26	's	's	PART
hls-11229	38	27	note	note	NOUN
hls-11229	38	28	:	:	PUNCT
hls-11229	38	29	all	all	DET
hls-11229	38	30	claims	claim	NOUN
hls-11229	38	31	expressed	express	VERB
hls-11229	38	32	in	in	ADP
hls-11229	38	33	this	this	DET
hls-11229	38	34	article	article	NOUN
hls-11229	38	35	are	be	AUX
hls-11229	38	36	solely	solely	ADV
hls-11229	38	37	those	those	PRON
hls-11229	38	38	of	of	ADP
hls-11229	38	39	the	the	DET
hls-11229	38	40	authors	author	NOUN
hls-11229	38	41	and	and	CCONJ
hls-11229	38	42	do	do	AUX
hls-11229	38	43	not	not	PART
hls-11229	38	44	necessarily	necessarily	ADV
hls-11229	38	45	represent	represent	VERB
hls-11229	38	46	those	those	PRON
hls-11229	38	47	of	of	ADP
hls-11229	38	48	their	their	PRON
hls-11229	38	49	affiliated	affiliated	ADJ
hls-11229	38	50	organizations	organization	NOUN
hls-11229	38	51	,	,	PUNCT
hls-11229	38	52	or	or	CCONJ
hls-11229	38	53	those	those	PRON
hls-11229	38	54	of	of	ADP
hls-11229	38	55	the	the	DET
hls-11229	38	56	publisher	publisher	NOUN
hls-11229	38	57	,	,	PUNCT
hls-11229	38	58	the	the	DET
hls-11229	38	59	editors	editor	NOUN
hls-11229	38	60	and	and	CCONJ
hls-11229	38	61	the	the	DET
hls-11229	38	62	reviewers	reviewer	NOUN
hls-11229	38	63	.	.	PUNCT
hls-11229	39	1	any	any	DET
hls-11229	39	2	product	product	NOUN
hls-11229	39	3	that	that	PRON
hls-11229	39	4	may	may	AUX
hls-11229	39	5	be	be	AUX
hls-11229	39	6	evaluated	evaluate	VERB
hls-11229	39	7	in	in	ADP
hls-11229	39	8	this	this	DET
hls-11229	39	9	article	article	NOUN
hls-11229	39	10	or	or	CCONJ
hls-11229	39	11	claim	claim	NOUN
hls-11229	39	12	that	that	PRON
hls-11229	39	13	may	may	AUX
hls-11229	39	14	be	be	AUX
hls-11229	39	15	made	make	VERB
hls-11229	39	16	by	by	ADP
hls-11229	39	17	its	its	PRON
hls-11229	39	18	manufacturer	manufacturer	NOUN
hls-11229	39	19	is	be	AUX
hls-11229	39	20	not	not	PART
hls-11229	39	21	guaranteed	guarantee	VERB
hls-11229	39	22	or	or	CCONJ
hls-11229	39	23	endorsed	endorse	VERB
hls-11229	39	24	by	by	ADP
hls-11229	39	25	the	the	DET
hls-11229	39	26	publisher.non	publisher.non	X
hls-11229	39	27	-co	-co	CCONJ
hls-11229	39	28	mmerc	mmerc	PROPN
hls-11229	39	29	ial	ial	PROPN
hls-11229	40	1	us	us	PROPN
hls-11229	40	2	e	e	NOUN
hls-11229	40	3	o	o	NOUN
hls-11229	40	4	nly	nly	ADV
hls-11229	40	5	resistance	resistance	NOUN
hls-11229	40	6	patterns	pattern	NOUN
hls-11229	40	7	to	to	ADP
hls-11229	40	8	crucial	crucial	ADJ
hls-11229	40	9	antibiotic	antibiotic	NOUN
hls-11229	40	10	of	of	ADP
hls-11229	40	11	clindamycin	clindamycin	NOUN
hls-11229	40	12	in	in	ADP
hls-11229	40	13	the	the	DET
hls-11229	40	14	management	management	NOUN
hls-11229	40	15	of	of	ADP
hls-11229	40	16	infections	infection	NOUN
hls-11229	40	17	caused	cause	VERB
hls-11229	40	18	by	by	ADP
hls-11229	40	19	s.	s.	PROPN
hls-11229	40	20	aureus	aureus	PROPN
hls-11229	40	21	.	.	PUNCT
hls-11229	41	1	material	material	NOUN
hls-11229	41	2	and	and	CCONJ
hls-11229	41	3	methods	method	NOUN
hls-11229	41	4	this	this	PRON
hls-11229	41	5	was	be	AUX
hls-11229	41	6	a	a	DET
hls-11229	41	7	prospective	prospective	ADJ
hls-11229	41	8	study	study	NOUN
hls-11229	41	9	carried	carry	VERB
hls-11229	41	10	out	out	ADP
hls-11229	41	11	over	over	ADP
hls-11229	41	12	a	a	DET
hls-11229	41	13	period	period	NOUN
hls-11229	41	14	of	of	ADP
hls-11229	41	15	one	one	NUM
hls-11229	41	16	and	and	CCONJ
hls-11229	41	17	a	a	DET
hls-11229	41	18	half	half	NOUN
hls-11229	41	19	year	year	NOUN
hls-11229	41	20	spanning	span	VERB
hls-11229	41	21	from	from	ADP
hls-11229	41	22	january	january	PROPN
hls-11229	41	23	2021	2021	NUM
hls-11229	41	24	to	to	ADP
hls-11229	41	25	june	june	PROPN
hls-11229	41	26	2022	2022	NUM
hls-11229	41	27	in	in	ADP
hls-11229	41	28	our	our	PRON
hls-11229	41	29	tertiary	tertiary	ADJ
hls-11229	41	30	care	care	NOUN
hls-11229	41	31	hospital	hospital	NOUN
hls-11229	41	32	of	of	ADP
hls-11229	41	33	delhi	delhi	PROPN
hls-11229	41	34	.	.	PUNCT
hls-11229	42	1	a	a	DET
hls-11229	42	2	total	total	NOUN
hls-11229	42	3	of	of	ADP
hls-11229	42	4	6586	6586	NUM
hls-11229	42	5	samples	sample	NOUN
hls-11229	42	6	,	,	PUNCT
hls-11229	42	7	including	include	VERB
hls-11229	42	8	pus	pus	PROPN
hls-11229	42	9	aspirates	aspirate	NOUN
hls-11229	42	10	,	,	PUNCT
hls-11229	42	11	peritoneal	peritoneal	ADJ
hls-11229	42	12	fluid	fluid	NOUN
hls-11229	42	13	,	,	PUNCT
hls-11229	42	14	pleural	pleural	ADJ
hls-11229	42	15	fluid	fluid	ADJ
hls-11229	42	16	,	,	PUNCT
hls-11229	42	17	synovial	synovial	ADJ
hls-11229	42	18	fluid	fluid	NOUN
hls-11229	42	19	,	,	PUNCT
hls-11229	42	20	respiratory	respiratory	ADJ
hls-11229	42	21	samples	sample	NOUN
hls-11229	42	22	,	,	PUNCT
hls-11229	42	23	and	and	CCONJ
hls-11229	42	24	genital	genital	ADJ
hls-11229	42	25	secretions	secretion	NOUN
hls-11229	42	26	were	be	AUX
hls-11229	42	27	received	receive	VERB
hls-11229	42	28	in	in	ADP
hls-11229	42	29	the	the	DET
hls-11229	42	30	microbiology	microbiology	NOUN
hls-11229	42	31	lab	lab	NOUN
hls-11229	42	32	of	of	ADP
hls-11229	42	33	our	our	PRON
hls-11229	42	34	hospital	hospital	NOUN
hls-11229	42	35	.	.	PUNCT
hls-11229	43	1	the	the	DET
hls-11229	43	2	samples	sample	NOUN
hls-11229	43	3	were	be	AUX
hls-11229	43	4	cultured	cultured	ADJ
hls-11229	43	5	on	on	ADP
hls-11229	43	6	blood	blood	NOUN
hls-11229	43	7	agar	agar	NOUN
hls-11229	43	8	,	,	PUNCT
hls-11229	43	9	macconkey	macconkey	NOUN
hls-11229	43	10	agar	agar	NOUN
hls-11229	43	11	and	and	CCONJ
hls-11229	43	12	chocolate	chocolate	NOUN
hls-11229	43	13	agar	agar	NOUN
hls-11229	43	14	using	use	VERB
hls-11229	43	15	standard	standard	ADJ
hls-11229	43	16	laboratory	laboratory	NOUN
hls-11229	43	17	protocols	protocol	NOUN
hls-11229	43	18	.	.	PUNCT
hls-11229	44	1	bacterial	bacterial	ADJ
hls-11229	44	2	identification	identification	NOUN
hls-11229	44	3	of	of	ADP
hls-11229	44	4	the	the	DET
hls-11229	44	5	growth	growth	NOUN
hls-11229	44	6	was	be	AUX
hls-11229	44	7	done	do	VERB
hls-11229	44	8	by	by	ADP
hls-11229	44	9	conventional	conventional	ADJ
hls-11229	44	10	methods	method	NOUN
hls-11229	44	11	,	,	PUNCT
hls-11229	44	12	using	use	VERB
hls-11229	44	13	biochemical	biochemical	ADJ
hls-11229	44	14	reactions	reaction	NOUN
hls-11229	44	15	(	(	PUNCT
hls-11229	44	16	catalase	catalase	NOUN
hls-11229	44	17	,	,	PUNCT
hls-11229	44	18	slide	slide	NOUN
hls-11229	44	19	and	and	CCONJ
hls-11229	44	20	tube	tube	NOUN
hls-11229	44	21	coagulase	coagulase	NOUN
hls-11229	44	22	,	,	PUNCT
hls-11229	44	23	mannitol	mannitol	NOUN
hls-11229	44	24	salt	salt	NOUN
hls-11229	44	25	agar	agar	NOUN
hls-11229	44	26	)	)	PUNCT
hls-11229	44	27	.	.	PUNCT
hls-11229	45	1	the	the	DET
hls-11229	45	2	samples	sample	NOUN
hls-11229	45	3	that	that	PRON
hls-11229	45	4	yielded	yield	VERB
hls-11229	45	5	growth	growth	NOUN
hls-11229	45	6	of	of	ADP
hls-11229	45	7	s.	s.	PROPN
hls-11229	45	8	aureus	aureus	PROPN
hls-11229	45	9	on	on	ADP
hls-11229	45	10	culture	culture	NOUN
hls-11229	45	11	were	be	AUX
hls-11229	45	12	further	far	ADV
hls-11229	45	13	subjected	subject	VERB
hls-11229	45	14	to	to	ADP
hls-11229	45	15	antimicrobial	antimicrobial	ADJ
hls-11229	45	16	susceptibility	susceptibility	NOUN
hls-11229	45	17	testing	testing	NOUN
hls-11229	45	18	(	(	PUNCT
hls-11229	45	19	ast	ast	NOUN
hls-11229	45	20	)	)	PUNCT
hls-11229	45	21	by	by	ADP
hls-11229	45	22	kirby	kirby	PROPN
hls-11229	45	23	bauer	bauer	PROPN
hls-11229	45	24	disk	disk	NOUN
hls-11229	45	25	diffusion	diffusion	NOUN
hls-11229	45	26	method	method	NOUN
hls-11229	45	27	,	,	PUNCT
hls-11229	45	28	according	accord	VERB
hls-11229	45	29	to	to	ADP
hls-11229	45	30	latest	late	ADJ
hls-11229	45	31	clsi	clsi	ADJ
hls-11229	45	32	guidelines.6	guidelines.6	NOUN
hls-11229	45	33	for	for	ADP
hls-11229	45	34	ast	ast	NOUN
hls-11229	45	35	0.5	0.5	NUM
hls-11229	45	36	mcfarland	mcfarland	NOUN
hls-11229	45	37	of	of	ADP
hls-11229	45	38	the	the	DET
hls-11229	45	39	strain	strain	NOUN
hls-11229	45	40	was	be	AUX
hls-11229	45	41	lawn	lawn	NOUN
hls-11229	45	42	cultured	cultured	ADJ
hls-11229	45	43	on	on	ADP
hls-11229	45	44	muller	muller	PROPN
hls-11229	45	45	hinton	hinton	PROPN
hls-11229	45	46	agar	agar	NOUN
hls-11229	45	47	,	,	PUNCT
hls-11229	45	48	followed	follow	VERB
hls-11229	45	49	by	by	ADP
hls-11229	45	50	placement	placement	NOUN
hls-11229	45	51	of	of	ADP
hls-11229	45	52	the	the	DET
hls-11229	45	53	antimicrobial	antimicrobial	ADJ
hls-11229	45	54	discs	disc	NOUN
hls-11229	45	55	at	at	ADP
hls-11229	45	56	a	a	DET
hls-11229	45	57	distance	distance	NOUN
hls-11229	45	58	of	of	ADP
hls-11229	45	59	15	15	NUM
hls-11229	45	60	-	-	SYM
hls-11229	45	61	20	20	NUM
hls-11229	45	62	mm	mm	NOUN
hls-11229	45	63	edge	edge	NOUN
hls-11229	45	64	to	to	PART
hls-11229	45	65	edge	edge	VERB
hls-11229	45	66	from	from	ADP
hls-11229	45	67	each	each	DET
hls-11229	45	68	other	other	ADJ
hls-11229	45	69	and	and	CCONJ
hls-11229	45	70	incubation	incubation	NOUN
hls-11229	45	71	at	at	ADP
hls-11229	45	72	35	35	NUM
hls-11229	45	73	°	°	NOUN
hls-11229	45	74	c±2	c±2	NOUN
hls-11229	45	75	°	°	NOUN
hls-11229	45	76	,	,	PUNCT
hls-11229	45	77	ambient	ambient	ADJ
hls-11229	45	78	air	air	NOUN
hls-11229	45	79	.	.	PUNCT
hls-11229	46	1	isolates	isolate	NOUN
hls-11229	46	2	were	be	AUX
hls-11229	46	3	classified	classify	VERB
hls-11229	46	4	as	as	SCONJ
hls-11229	46	5	methicillin	methicillin	NOUN
hls-11229	46	6	susceptible	susceptible	ADJ
hls-11229	46	7	or	or	CCONJ
hls-11229	46	8	resistant	resistant	ADJ
hls-11229	46	9	on	on	ADP
hls-11229	46	10	the	the	DET
hls-11229	46	11	basis	basis	NOUN
hls-11229	46	12	of	of	ADP
hls-11229	46	13	zone	zone	NOUN
hls-11229	46	14	of	of	ADP
hls-11229	46	15	inhibition	inhibition	NOUN
hls-11229	46	16	diameters	diameter	NOUN
hls-11229	46	17	of	of	ADP
hls-11229	46	18	cefoxitin	cefoxitin	NOUN
hls-11229	46	19	.	.	PUNCT
hls-11229	47	1	while	while	SCONJ
hls-11229	47	2	,	,	PUNCT
hls-11229	47	3	presence	presence	NOUN
hls-11229	47	4	of	of	ADP
hls-11229	47	5	clindamycin	clindamycin	NOUN
hls-11229	47	6	resistance	resistance	NOUN
hls-11229	47	7	(	(	PUNCT
hls-11229	47	8	constitutive	constitutive	ADJ
hls-11229	47	9	,	,	PUNCT
hls-11229	47	10	inducible	inducible	ADJ
hls-11229	47	11	and	and	CCONJ
hls-11229	47	12	msb	msb	PROPN
hls-11229	47	13	)	)	PUNCT
hls-11229	47	14	was	be	AUX
hls-11229	47	15	determined	determine	VERB
hls-11229	47	16	by	by	ADP
hls-11229	47	17	performing	perform	VERB
hls-11229	47	18	disk	disk	NOUN
hls-11229	47	19	diffusion	diffusion	NOUN
hls-11229	47	20	method	method	NOUN
hls-11229	47	21	,	,	PUNCT
hls-11229	47	22	placing	place	VERB
hls-11229	47	23	erythromycin	erythromycin	NOUN
hls-11229	47	24	(	(	PUNCT
hls-11229	47	25	15	15	NUM
hls-11229	47	26	µg	µg	NOUN
hls-11229	47	27	)	)	PUNCT
hls-11229	47	28	and	and	CCONJ
hls-11229	47	29	clindamycin	clindamycin	NOUN
hls-11229	47	30	(	(	PUNCT
hls-11229	47	31	2	2	NUM
hls-11229	47	32	µg	µg	NOUN
hls-11229	47	33	)	)	PUNCT
hls-11229	47	34	at	at	ADP
hls-11229	47	35	a	a	DET
hls-11229	47	36	distance	distance	NOUN
hls-11229	47	37	of	of	ADP
hls-11229	47	38	15	15	NUM
hls-11229	47	39	-	-	SYM
hls-11229	47	40	26	26	NUM
hls-11229	47	41	mm	mm	NOUN
hls-11229	47	42	from	from	ADP
hls-11229	47	43	each	each	DET
hls-11229	47	44	other	other	ADJ
hls-11229	47	45	.	.	PUNCT
hls-11229	48	1	zone	zone	NOUN
hls-11229	48	2	cut	cut	NOUN
hls-11229	48	3	-	-	PUNCT
hls-11229	48	4	offs	off	NOUN
hls-11229	48	5	for	for	ADP
hls-11229	48	6	the	the	DET
hls-11229	48	7	antibiotics	antibiotic	NOUN
hls-11229	48	8	have	have	AUX
hls-11229	48	9	been	be	AUX
hls-11229	48	10	descried	descry	VERB
hls-11229	48	11	in	in	ADP
hls-11229	48	12	the	the	DET
hls-11229	48	13	table	table	NOUN
hls-11229	48	14	1	1	NUM
hls-11229	48	15	.	.	PUNCT
hls-11229	49	1	isolates	isolate	NOUN
hls-11229	49	2	with	with	ADP
hls-11229	49	3	intermediate	intermediate	ADJ
hls-11229	49	4	zone	zone	NOUN
hls-11229	49	5	diameters	diameter	NOUN
hls-11229	49	6	were	be	AUX
hls-11229	49	7	considered	consider	VERB
hls-11229	49	8	as	as	ADP
hls-11229	49	9	resistant	resistant	ADJ
hls-11229	49	10	for	for	ADP
hls-11229	49	11	icr	icr	PROPN
hls-11229	49	12	analysis	analysis	NOUN
hls-11229	49	13	.	.	PUNCT
hls-11229	50	1	presence	presence	NOUN
hls-11229	50	2	of	of	ADP
hls-11229	50	3	d	d	NOUN
hls-11229	50	4	-	-	NOUN
hls-11229	50	5	zone	zone	NOUN
hls-11229	50	6	i.e.	i.e.	ADV
hls-11229	50	7	,	,	PUNCT
hls-11229	50	8	flattening	flattening	NOUN
hls-11229	50	9	of	of	ADP
hls-11229	50	10	the	the	DET
hls-11229	50	11	zone	zone	NOUN
hls-11229	50	12	of	of	ADP
hls-11229	50	13	inhibition	inhibition	NOUN
hls-11229	50	14	adjacent	adjacent	ADJ
hls-11229	50	15	to	to	ADP
hls-11229	50	16	the	the	DET
hls-11229	50	17	erythromycin	erythromycin	NOUN
hls-11229	50	18	disc	disc	NOUN
hls-11229	50	19	was	be	AUX
hls-11229	50	20	interpreted	interpret	VERB
hls-11229	50	21	as	as	ADP
hls-11229	50	22	inducible	inducible	ADJ
hls-11229	50	23	clindamycin	clindamycin	NOUN
hls-11229	50	24	resistance	resistance	NOUN
hls-11229	50	25	,	,	PUNCT
hls-11229	50	26	as	as	SCONJ
hls-11229	50	27	shown	show	VERB
hls-11229	50	28	in	in	ADP
hls-11229	50	29	figure	figure	NOUN
hls-11229	50	30	1a	1a	NOUN
hls-11229	50	31	.	.	PUNCT
hls-11229	51	1	results	result	NOUN
hls-11229	51	2	out	out	ADP
hls-11229	51	3	of	of	ADP
hls-11229	51	4	the	the	DET
hls-11229	51	5	total	total	ADJ
hls-11229	51	6	6586	6586	NUM
hls-11229	51	7	pyogenic	pyogenic	ADJ
hls-11229	51	8	and	and	CCONJ
hls-11229	51	9	respiratory	respiratory	ADJ
hls-11229	51	10	samples	sample	NOUN
hls-11229	51	11	received	receive	VERB
hls-11229	51	12	,	,	PUNCT
hls-11229	51	13	s.	s.	PROPN
hls-11229	51	14	aureus	aureus	PROPN
hls-11229	51	15	was	be	AUX
hls-11229	51	16	isolated	isolate	VERB
hls-11229	51	17	from	from	ADP
hls-11229	51	18	11.4	11.4	NUM
hls-11229	51	19	%	%	NOUN
hls-11229	51	20	(	(	PUNCT
hls-11229	51	21	752/6586	752/6586	NUM
hls-11229	51	22	)	)	PUNCT
hls-11229	51	23	samples	sample	NOUN
hls-11229	51	24	.	.	PUNCT
hls-11229	52	1	majority	majority	NOUN
hls-11229	52	2	of	of	ADP
hls-11229	52	3	these	these	DET
hls-11229	52	4	samples	sample	NOUN
hls-11229	52	5	were	be	AUX
hls-11229	52	6	received	receive	VERB
hls-11229	52	7	from	from	ADP
hls-11229	52	8	the	the	DET
hls-11229	52	9	patients	patient	NOUN
hls-11229	52	10	admitted	admit	VERB
hls-11229	52	11	in	in	ADP
hls-11229	52	12	surgical	surgical	ADJ
hls-11229	52	13	wards	ward	NOUN
hls-11229	52	14	.	.	PUNCT
hls-11229	53	1	the	the	DET
hls-11229	53	2	organism	organism	NOUN
hls-11229	53	3	was	be	AUX
hls-11229	53	4	isolated	isolate	VERB
hls-11229	53	5	more	more	ADV
hls-11229	53	6	commonly	commonly	ADV
hls-11229	53	7	from	from	ADP
hls-11229	53	8	the	the	DET
hls-11229	53	9	male	male	ADJ
hls-11229	53	10	population	population	NOUN
hls-11229	53	11	(	(	PUNCT
hls-11229	53	12	54.9	54.9	NUM
hls-11229	53	13	%	%	NOUN
hls-11229	53	14	)	)	PUNCT
hls-11229	53	15	as	as	SCONJ
hls-11229	53	16	compared	compare	VERB
hls-11229	53	17	to	to	ADP
hls-11229	53	18	the	the	DET
hls-11229	53	19	females	female	NOUN
hls-11229	53	20	(	(	PUNCT
hls-11229	53	21	45.07	45.07	NUM
hls-11229	53	22	%	%	NOUN
hls-11229	53	23	)	)	PUNCT
hls-11229	53	24	.	.	PUNCT
hls-11229	54	1	isolation	isolation	NOUN
hls-11229	54	2	of	of	ADP
hls-11229	54	3	s.	s.	PROPN
hls-11229	54	4	aureus	aureus	PROPN
hls-11229	54	5	was	be	AUX
hls-11229	54	6	more	more	ADV
hls-11229	54	7	common	common	ADJ
hls-11229	54	8	from	from	ADP
hls-11229	54	9	adult	adult	NOUN
hls-11229	54	10	patient	patient	ADJ
hls-11229	54	11	population	population	NOUN
hls-11229	54	12	(	(	PUNCT
hls-11229	54	13	71.8	71.8	NUM
hls-11229	54	14	%	%	NOUN
hls-11229	54	15	)	)	PUNCT
hls-11229	54	16	in	in	ADP
hls-11229	54	17	comparison	comparison	NOUN
hls-11229	54	18	to	to	ADP
hls-11229	54	19	the	the	DET
hls-11229	54	20	paediatric	paediatric	ADJ
hls-11229	54	21	population	population	NOUN
hls-11229	54	22	(	(	PUNCT
hls-11229	54	23	28.9	28.9	NUM
hls-11229	54	24	%	%	NOUN
hls-11229	54	25	)	)	PUNCT
hls-11229	54	26	.	.	PUNCT
hls-11229	55	1	of	of	ADP
hls-11229	55	2	the	the	DET
hls-11229	55	3	total	total	ADJ
hls-11229	55	4	s.	s.	PROPN
hls-11229	55	5	aureus	aureus	PROPN
hls-11229	55	6	isolates	isolate	VERB
hls-11229	55	7	335	335	NUM
hls-11229	55	8	(	(	PUNCT
hls-11229	55	9	44.54	44.54	NUM
hls-11229	55	10	%	%	NOUN
hls-11229	55	11	)	)	PUNCT
hls-11229	55	12	were	be	AUX
hls-11229	55	13	mssa	mssa	ADJ
hls-11229	55	14	(	(	PUNCT
hls-11229	55	15	methicillin	methicillin	NOUN
hls-11229	55	16	sensitive	sensitive	ADJ
hls-11229	55	17	staphylococcus	staphylococcus	NOUN
hls-11229	55	18	aureus	aureus	NOUN
hls-11229	55	19	)	)	PUNCT
hls-11229	55	20	,	,	PUNCT
hls-11229	55	21	while	while	SCONJ
hls-11229	55	22	417	417	NUM
hls-11229	55	23	(	(	PUNCT
hls-11229	55	24	55.45	55.45	NUM
hls-11229	55	25	%	%	NOUN
hls-11229	55	26	)	)	PUNCT
hls-11229	55	27	were	be	AUX
hls-11229	55	28	mrsa	mrsa	NOUN
hls-11229	55	29	(	(	PUNCT
hls-11229	55	30	methicillin	methicillin	NOUN
hls-11229	55	31	resistant	resistant	ADJ
hls-11229	55	32	staphylococcus	staphylococcus	NOUN
hls-11229	55	33	aureus	aureus	NOUN
hls-11229	55	34	.	.	PUNCT
hls-11229	56	1	all	all	DET
hls-11229	56	2	the	the	DET
hls-11229	56	3	strains	strain	NOUN
hls-11229	56	4	of	of	ADP
hls-11229	56	5	this	this	DET
hls-11229	56	6	gram	gram	ADJ
hls-11229	56	7	-	-	PUNCT
hls-11229	56	8	positive	positive	ADJ
hls-11229	56	9	organism	organism	NOUN
hls-11229	56	10	were	be	AUX
hls-11229	56	11	tested	test	VERB
hls-11229	56	12	for	for	ADP
hls-11229	56	13	different	different	ADJ
hls-11229	56	14	mlsb	mlsb	NOUN
hls-11229	56	15	phenotypes	phenotype	NOUN
hls-11229	56	16	i.e.	i.e.	ADV
hls-11229	56	17	,	,	PUNCT
hls-11229	56	18	inducible	inducible	ADJ
hls-11229	56	19	,	,	PUNCT
hls-11229	56	20	constitutive	constitutive	ADJ
hls-11229	56	21	and	and	CCONJ
hls-11229	56	22	msb	msb	PROPN
hls-11229	56	23	.	.	PROPN
hls-11229	57	1	inducible	inducible	ADJ
hls-11229	57	2	clindamycin	clindamycin	NOUN
hls-11229	57	3	resistance	resistance	NOUN
hls-11229	57	4	was	be	AUX
hls-11229	57	5	found	find	VERB
hls-11229	57	6	in	in	ADP
hls-11229	57	7	16.35	16.35	NUM
hls-11229	57	8	%	%	NOUN
hls-11229	57	9	of	of	ADP
hls-11229	57	10	the	the	DET
hls-11229	57	11	isolates	isolate	NOUN
hls-11229	57	12	;	;	PUNCT
hls-11229	57	13	constitutive	constitutive	ADJ
hls-11229	57	14	clindamycin	clindamycin	NOUN
hls-11229	57	15	resistance	resistance	NOUN
hls-11229	57	16	was	be	AUX
hls-11229	57	17	observed	observe	VERB
hls-11229	57	18	in	in	ADP
hls-11229	57	19	19.28	19.28	NUM
hls-11229	57	20	%	%	NOUN
hls-11229	57	21	of	of	ADP
hls-11229	57	22	the	the	DET
hls-11229	57	23	observed	observed	ADJ
hls-11229	57	24	isolates	isolate	NOUN
hls-11229	57	25	,	,	PUNCT
hls-11229	57	26	while	while	SCONJ
hls-11229	57	27	msb	msb	PROPN
hls-11229	57	28	phenotypes	phenotype	NOUN
hls-11229	57	29	were	be	AUX
hls-11229	57	30	observed	observe	VERB
hls-11229	57	31	in	in	ADP
hls-11229	57	32	43.08	43.08	NUM
hls-11229	57	33	%	%	NOUN
hls-11229	57	34	.	.	PUNCT
hls-11229	58	1	percentage	percentage	NOUN
hls-11229	58	2	distribution	distribution	NOUN
hls-11229	58	3	of	of	ADP
hls-11229	58	4	various	various	ADJ
hls-11229	58	5	mlsb	mlsb	NOUN
hls-11229	58	6	phenotypes	phenotype	NOUN
hls-11229	58	7	has	have	AUX
hls-11229	58	8	been	be	AUX
hls-11229	58	9	described	describe	VERB
hls-11229	58	10	in	in	ADP
hls-11229	58	11	table	table	NOUN
hls-11229	58	12	2	2	NUM
hls-11229	58	13	.	.	PUNCT
hls-11229	59	1	distribution	distribution	NOUN
hls-11229	59	2	of	of	ADP
hls-11229	59	3	mssa	mssa	NOUN
hls-11229	59	4	and	and	CCONJ
hls-11229	59	5	mrsa	mrsa	NOUN
hls-11229	59	6	were	be	AUX
hls-11229	59	7	also	also	ADV
hls-11229	59	8	observed	observe	VERB
hls-11229	59	9	among	among	ADP
hls-11229	59	10	the	the	DET
hls-11229	59	11	mlsb	mlsb	PROPN
hls-11229	59	12	phenotypes	phenotype	NOUN
hls-11229	59	13	(	(	PUNCT
hls-11229	59	14	table	table	NOUN
hls-11229	59	15	3	3	NUM
hls-11229	59	16	)	)	PUNCT
hls-11229	59	17	.	.	PUNCT
hls-11229	60	1	on	on	ADP
hls-11229	60	2	application	application	NOUN
hls-11229	60	3	of	of	ADP
hls-11229	60	4	fischer	fischer	PROPN
hls-11229	60	5	’s	’s	PART
hls-11229	60	6	exact	exact	ADJ
hls-11229	60	7	test	test	NOUN
hls-11229	60	8	,	,	PUNCT
hls-11229	60	9	no	no	DET
hls-11229	60	10	significant	significant	ADJ
hls-11229	60	11	association	association	NOUN
hls-11229	60	12	was	be	AUX
hls-11229	60	13	observed	observe	VERB
hls-11229	60	14	between	between	ADP
hls-11229	60	15	methicillin	methicillin	NOUN
hls-11229	60	16	susceptibility	susceptibility	NOUN
hls-11229	60	17	of	of	ADP
hls-11229	60	18	the	the	DET
hls-11229	60	19	isolates	isolate	NOUN
hls-11229	60	20	and	and	CCONJ
hls-11229	60	21	the	the	DET
hls-11229	60	22	constitutive	constitutive	NOUN
hls-11229	60	23	and	and	CCONJ
hls-11229	60	24	msb	msb	PROPN
hls-11229	60	25	phe	phe	PROPN
hls-11229	60	26	article	article	PROPN
hls-11229	60	27	table	table	VERB
hls-11229	60	28	1	1	NUM
hls-11229	60	29	.	.	PUNCT
hls-11229	60	30	antimicrobial	antimicrobial	ADJ
hls-11229	60	31	susceptibility	susceptibility	NOUN
hls-11229	60	32	break	break	NOUN
hls-11229	60	33	points	point	NOUN
hls-11229	60	34	(	(	PUNCT
hls-11229	60	35	clsi	clsi	NOUN
hls-11229	60	36	2022	2022	NUM
hls-11229	60	37	)	)	PUNCT
hls-11229	60	38	.	.	PUNCT
hls-11229	61	1	antibiotic	antibiotic	ADJ
hls-11229	61	2	susceptible	susceptible	ADJ
hls-11229	61	3	intermediate	intermediate	ADJ
hls-11229	61	4	resistant	resistant	ADJ
hls-11229	61	5	erythromycin	erythromycin	NOUN
hls-11229	61	6	(	(	PUNCT
hls-11229	61	7	15	15	NUM
hls-11229	61	8	µg	µg	NOUN
hls-11229	61	9	)	)	PUNCT
hls-11229	61	10	≥23	≥23	NUM
hls-11229	61	11	mm	mm	PROPN
hls-11229	61	12	14	14	NUM
hls-11229	61	13	-	-	SYM
hls-11229	61	14	22	22	NUM
hls-11229	61	15	mm	mm	INTJ
hls-11229	61	16	≤13	≤13	INTJ
hls-11229	61	17	mm	mm	INTJ
hls-11229	61	18	clindamycin	clindamycin	NOUN
hls-11229	61	19	(	(	PUNCT
hls-11229	61	20	2	2	NUM
hls-11229	61	21	µg	µg	NOUN
hls-11229	61	22	)	)	PUNCT
hls-11229	61	23	≥21	≥21	ADP
hls-11229	61	24	mm	mm	PROPN
hls-11229	61	25	15	15	NUM
hls-11229	61	26	-	-	SYM
hls-11229	61	27	20	20	NUM
hls-11229	61	28	mm	mm	INTJ
hls-11229	61	29	≤14	≤14	PRON
hls-11229	61	30	mm	mm	NOUN
hls-11229	61	31	cefoxitin	cefoxitin	NOUN
hls-11229	61	32	(	(	PUNCT
hls-11229	61	33	30	30	NUM
hls-11229	61	34	µg	µg	NOUN
hls-11229	61	35	)	)	PUNCT
hls-11229	61	36	≥22	≥22	ADP
hls-11229	61	37	mm	mm	PROPN
hls-11229	61	38	≤21	≤21	ADJ
hls-11229	61	39	mm	mm	NOUN
hls-11229	61	40	table	table	NOUN
hls-11229	61	41	2	2	NUM
hls-11229	61	42	.	.	PUNCT
hls-11229	61	43	distribution	distribution	NOUN
hls-11229	61	44	of	of	ADP
hls-11229	61	45	various	various	ADJ
hls-11229	61	46	mlsb	mlsb	NOUN
hls-11229	61	47	phenotypes	phenotype	NOUN
hls-11229	61	48	among	among	ADP
hls-11229	61	49	staphylococcal	staphylococcal	ADJ
hls-11229	61	50	aureus	aureus	NOUN
hls-11229	61	51	isolates	isolate	NOUN
hls-11229	61	52	from	from	ADP
hls-11229	61	53	clinical	clinical	ADJ
hls-11229	61	54	samples	sample	NOUN
hls-11229	61	55	(	(	PUNCT
hls-11229	61	56	n=752	n=752	NUM
hls-11229	61	57	)	)	PUNCT
hls-11229	61	58	.	.	PUNCT
hls-11229	62	1	erythromycin	erythromycin	VERB
hls-11229	62	2	clindamycin	clindamycin	NOUN
hls-11229	62	3	d	d	NOUN
hls-11229	62	4	test	test	NOUN
hls-11229	62	5	phenotype	phenotype	NOUN
hls-11229	62	6	no	no	INTJ
hls-11229	62	7	.	.	PUNCT
hls-11229	63	1	of	of	ADP
hls-11229	63	2	isolates	isolate	NOUN
hls-11229	63	3	percentage	percentage	NOUN
hls-11229	63	4	susceptibility	susceptibility	NOUN
hls-11229	63	5	susceptibility	susceptibility	NOUN
hls-11229	63	6	susceptible	susceptible	ADJ
hls-11229	63	7	susceptible	susceptible	ADJ
hls-11229	63	8	negative	negative	ADJ
hls-11229	63	9	160	160	NUM
hls-11229	63	10	21.27	21.27	NUM
hls-11229	63	11	resistant	resistant	ADJ
hls-11229	63	12	resistant	resistant	ADJ
hls-11229	63	13	negative	negative	ADJ
hls-11229	63	14	cmlsb	cmlsb	NOUN
hls-11229	63	15	145	145	NUM
hls-11229	63	16	19.28	19.28	NUM
hls-11229	63	17	resistant	resistant	ADJ
hls-11229	63	18	susceptible	susceptible	ADJ
hls-11229	63	19	positive	positive	ADJ
hls-11229	63	20	imlsb	imlsb	NOUN
hls-11229	63	21	123	123	NUM
hls-11229	63	22	16.35	16.35	NUM
hls-11229	63	23	resistant	resistant	ADJ
hls-11229	63	24	susceptible	susceptible	ADJ
hls-11229	63	25	negative	negative	ADJ
hls-11229	63	26	msb	msb	PROPN
hls-11229	63	27	324	324	NUM
hls-11229	63	28	43.08	43.08	NUM
hls-11229	63	29	figure	figure	NOUN
hls-11229	63	30	1	1	NUM
hls-11229	63	31	.	.	PUNCT
hls-11229	64	1	identification	identification	NOUN
hls-11229	64	2	of	of	ADP
hls-11229	64	3	various	various	ADJ
hls-11229	64	4	mlsb	mlsb	NOUN
hls-11229	64	5	phenotypes	phenotype	NOUN
hls-11229	64	6	of	of	ADP
hls-11229	64	7	staphylococcal	staphylococcal	ADJ
hls-11229	64	8	aureus	aureus	NOUN
hls-11229	64	9	isolates	isolate	NOUN
hls-11229	64	10	from	from	ADP
hls-11229	64	11	clinical	clinical	ADJ
hls-11229	64	12	samples	sample	NOUN
hls-11229	64	13	(	(	PUNCT
hls-11229	64	14	n=752	n=752	NUM
hls-11229	64	15	):	):	PUNCT
hls-11229	64	16	a	a	X
hls-11229	64	17	)	)	PUNCT
hls-11229	64	18	inducible	inducible	ADJ
hls-11229	64	19	mlsb	mlsb	NOUN
hls-11229	64	20	(	(	PUNCT
hls-11229	64	21	imlsb	imlsb	PROPN
hls-11229	64	22	)	)	PUNCT
hls-11229	64	23	;	;	PUNCT
hls-11229	64	24	b	b	X
hls-11229	64	25	)	)	PUNCT
hls-11229	64	26	constitutive	constitutive	ADJ
hls-11229	64	27	mlsb	mlsb	NOUN
hls-11229	64	28	(	(	PUNCT
hls-11229	64	29	cmlsb	cmlsb	PROPN
hls-11229	64	30	)	)	PUNCT
hls-11229	64	31	.	.	PUNCT
hls-11229	65	1	[	[	X
hls-11229	65	2	healthcare	healthcare	NOUN
hls-11229	65	3	in	in	ADP
hls-11229	65	4	low	low	ADJ
hls-11229	65	5	-	-	PUNCT
hls-11229	65	6	resource	resource	NOUN
hls-11229	65	7	settings	setting	NOUN
hls-11229	65	8	2023	2023	NUM
hls-11229	65	9	;	;	PUNCT
hls-11229	65	10	11:11229	11:11229	NUM
hls-11229	65	11	]	]	X
hls-11229	66	1	[	[	X
hls-11229	66	2	page	page	NOUN
hls-11229	66	3	27	27	NUM
hls-11229	66	4	]	]	PUNCT
hls-11229	66	5	non	non	ADJ
hls-11229	66	6	-co	-co	PROPN
hls-11229	66	7	mmerc	mmerc	PROPN
hls-11229	66	8	ial	ial	PROPN
hls-11229	66	9	us	us	PROPN
hls-11229	66	10	e	e	NOUN
hls-11229	66	11	o	o	NOUN
hls-11229	66	12	nly	nly	ADV
hls-11229	66	13	notypes	notype	NOUN
hls-11229	66	14	,	,	PUNCT
hls-11229	66	15	as	as	SCONJ
hls-11229	66	16	the	the	DET
hls-11229	66	17	p	p	NOUN
hls-11229	66	18	value	value	NOUN
hls-11229	66	19	was	be	AUX
hls-11229	66	20	found	find	VERB
hls-11229	66	21	to	to	PART
hls-11229	66	22	be	be	AUX
hls-11229	66	23	0.0556	0.0556	NUM
hls-11229	66	24	.	.	PUNCT
hls-11229	66	25	association	association	NOUN
hls-11229	66	26	of	of	ADP
hls-11229	66	27	methicillin	methicillin	PROPN
hls-11229	66	28	susceptibility	susceptibility	NOUN
hls-11229	66	29	was	be	AUX
hls-11229	66	30	established	establish	VERB
hls-11229	66	31	in	in	ADP
hls-11229	66	32	the	the	DET
hls-11229	66	33	isolates	isolate	NOUN
hls-11229	66	34	displaying	display	VERB
hls-11229	66	35	inducible	inducible	ADJ
hls-11229	66	36	clindamycin	clindamycin	NOUN
hls-11229	66	37	resistance	resistance	NOUN
hls-11229	66	38	.	.	PUNCT
hls-11229	67	1	of	of	ADP
hls-11229	67	2	the	the	DET
hls-11229	67	3	total	total	ADJ
hls-11229	67	4	123	123	NUM
hls-11229	67	5	isolates	isolate	NOUN
hls-11229	67	6	showing	show	VERB
hls-11229	67	7	inducible	inducible	ADJ
hls-11229	67	8	clindamycin	clindamycin	NOUN
hls-11229	67	9	resistance	resistance	NOUN
hls-11229	67	10	,	,	PUNCT
hls-11229	67	11	29.2	29.2	NUM
hls-11229	67	12	%	%	NOUN
hls-11229	67	13	were	be	AUX
hls-11229	67	14	methicillin	methicillin	NOUN
hls-11229	67	15	susceptible	susceptible	ADJ
hls-11229	67	16	while	while	SCONJ
hls-11229	67	17	the	the	DET
hls-11229	67	18	rest	rest	NOUN
hls-11229	67	19	71	71	NUM
hls-11229	67	20	%	%	NOUN
hls-11229	67	21	were	be	AUX
hls-11229	67	22	found	find	VERB
hls-11229	67	23	to	to	PART
hls-11229	67	24	be	be	AUX
hls-11229	67	25	methicillin	methicillin	NOUN
hls-11229	67	26	resistant	resistant	ADJ
hls-11229	67	27	(	(	PUNCT
hls-11229	67	28	figure	figure	NOUN
hls-11229	67	29	2	2	NUM
hls-11229	67	30	)	)	PUNCT
hls-11229	67	31	.	.	PUNCT
hls-11229	68	1	no	no	DET
hls-11229	68	2	significant	significant	ADJ
hls-11229	68	3	association	association	NOUN
hls-11229	68	4	was	be	AUX
hls-11229	68	5	observed	observe	VERB
hls-11229	68	6	between	between	ADP
hls-11229	68	7	icr	icr	PROPN
hls-11229	68	8	phenotype	phenotype	NOUN
hls-11229	68	9	and	and	CCONJ
hls-11229	68	10	methicillin	methicillin	NOUN
hls-11229	68	11	susceptibility	susceptibility	NOUN
hls-11229	68	12	(	(	PUNCT
hls-11229	68	13	p≥0.05	p≥0.05	NOUN
hls-11229	68	14	)	)	PUNCT
hls-11229	68	15	.	.	PUNCT
hls-11229	69	1	discussion	discussion	NOUN
hls-11229	69	2	s.	s.	PROPN
hls-11229	69	3	aureus	aureus	PROPN
hls-11229	69	4	is	be	AUX
hls-11229	69	5	the	the	DET
hls-11229	69	6	most	most	ADV
hls-11229	69	7	common	common	ADJ
hls-11229	69	8	aetiological	aetiological	ADJ
hls-11229	69	9	agent	agent	NOUN
hls-11229	69	10	of	of	ADP
hls-11229	69	11	pyogenic	pyogenic	ADJ
hls-11229	69	12	infections	infection	NOUN
hls-11229	69	13	.	.	PUNCT
hls-11229	70	1	drugs	drug	NOUN
hls-11229	70	2	such	such	ADJ
hls-11229	70	3	as	as	ADP
hls-11229	70	4	trimethoprim	trimethoprim	ADJ
hls-11229	70	5	-	-	PUNCT
hls-11229	70	6	sulfamethoxazole	sulfamethoxazole	NOUN
hls-11229	70	7	,	,	PUNCT
hls-11229	70	8	tetracyclines	tetracycline	NOUN
hls-11229	70	9	(	(	PUNCT
hls-11229	70	10	minocycline	minocycline	NOUN
hls-11229	70	11	and	and	CCONJ
hls-11229	70	12	doxycycline	doxycycline	NOUN
hls-11229	70	13	)	)	PUNCT
hls-11229	70	14	and	and	CCONJ
hls-11229	70	15	clindamycin	clindamycin	NOUN
hls-11229	70	16	have	have	AUX
hls-11229	70	17	gained	gain	VERB
hls-11229	70	18	importance	importance	NOUN
hls-11229	70	19	in	in	ADP
hls-11229	70	20	present	present	ADJ
hls-11229	70	21	scenario	scenario	NOUN
hls-11229	70	22	of	of	ADP
hls-11229	70	23	increasing	increase	VERB
hls-11229	70	24	drug	drug	NOUN
hls-11229	70	25	resistance	resistance	NOUN
hls-11229	70	26	in	in	ADP
hls-11229	70	27	staphylococcal	staphylococcal	ADJ
hls-11229	70	28	isolates.7	isolates.7	NOUN
hls-11229	70	29	clindamycin	clindamycin	NOUN
hls-11229	70	30	,	,	PUNCT
hls-11229	70	31	belongs	belong	VERB
hls-11229	70	32	to	to	ADP
hls-11229	70	33	the	the	DET
hls-11229	70	34	lincosamide	lincosamide	ADJ
hls-11229	70	35	group	group	NOUN
hls-11229	70	36	of	of	ADP
hls-11229	70	37	antibiotics	antibiotic	NOUN
hls-11229	70	38	and	and	CCONJ
hls-11229	70	39	possesses	possess	VERB
hls-11229	70	40	activity	activity	NOUN
hls-11229	70	41	against	against	ADP
hls-11229	70	42	gram	gram	NOUN
hls-11229	70	43	-	-	PUNCT
hls-11229	70	44	positive	positive	ADJ
hls-11229	70	45	as	as	ADV
hls-11229	70	46	well	well	ADV
hls-11229	70	47	as	as	ADP
hls-11229	70	48	anaerobic	anaerobic	ADJ
hls-11229	70	49	bacteria	bacteria	NOUN
hls-11229	70	50	.	.	PUNCT
hls-11229	71	1	its	its	PRON
hls-11229	71	2	properties	property	NOUN
hls-11229	71	3	such	such	ADJ
hls-11229	71	4	as	as	ADP
hls-11229	71	5	good	good	ADJ
hls-11229	71	6	tissue	tissue	NOUN
hls-11229	71	7	penetration	penetration	NOUN
hls-11229	71	8	,	,	PUNCT
hls-11229	71	9	cost	cost	NOUN
hls-11229	71	10	,	,	PUNCT
hls-11229	71	11	spectrum	spectrum	NOUN
hls-11229	71	12	and	and	CCONJ
hls-11229	71	13	,	,	PUNCT
hls-11229	71	14	oral	oral	ADJ
hls-11229	71	15	bioavailability	bioavailability	NOUN
hls-11229	71	16	make	make	VERB
hls-11229	71	17	clindamycin	clindamycin	NOUN
hls-11229	71	18	conducive	conducive	ADJ
hls-11229	71	19	to	to	ADP
hls-11229	71	20	treating	treat	VERB
hls-11229	71	21	infections	infection	NOUN
hls-11229	71	22	.	.	PUNCT
hls-11229	72	1	it	it	PRON
hls-11229	72	2	is	be	AUX
hls-11229	72	3	thus	thus	ADV
hls-11229	72	4	,	,	PUNCT
hls-11229	72	5	used	use	VERB
hls-11229	72	6	for	for	ADP
hls-11229	72	7	skin	skin	NOUN
hls-11229	72	8	and	and	CCONJ
hls-11229	72	9	soft	soft	ADJ
hls-11229	72	10	tissue	tissue	NOUN
hls-11229	72	11	infections	infection	NOUN
hls-11229	72	12	,	,	PUNCT
hls-11229	72	13	with	with	ADP
hls-11229	72	14	particular	particular	ADJ
hls-11229	72	15	significance	significance	NOUN
hls-11229	72	16	in	in	ADP
hls-11229	72	17	cases	case	NOUN
hls-11229	72	18	of	of	ADP
hls-11229	72	19	ca	ca	NOUN
hls-11229	72	20	-	-	PUNCT
hls-11229	72	21	mrsa	mrsa	NOUN
hls-11229	72	22	infections	infection	NOUN
hls-11229	72	23	,	,	PUNCT
hls-11229	72	24	wherein	wherein	SCONJ
hls-11229	72	25	an	an	DET
hls-11229	72	26	oral	oral	ADJ
hls-11229	72	27	treatment	treatment	NOUN
hls-11229	72	28	regimen	regiman	NOUN
hls-11229	72	29	can	can	AUX
hls-11229	72	30	suffice	suffice	VERB
hls-11229	72	31	for	for	ADP
hls-11229	72	32	the	the	DET
hls-11229	72	33	patient	patient	NOUN
hls-11229	72	34	.	.	PUNCT
hls-11229	73	1	this	this	DET
hls-11229	73	2	lincosamide	lincosamide	ADJ
hls-11229	73	3	antibiotic	antibiotic	NOUN
hls-11229	73	4	is	be	AUX
hls-11229	73	5	also	also	ADV
hls-11229	73	6	effective	effective	ADJ
hls-11229	73	7	in	in	ADP
hls-11229	73	8	treating	treat	VERB
hls-11229	73	9	conditions	condition	NOUN
hls-11229	73	10	such	such	ADJ
hls-11229	73	11	as	as	ADP
hls-11229	73	12	pleural	pleural	ADJ
hls-11229	73	13	empyema	empyema	NOUN
hls-11229	73	14	,	,	PUNCT
hls-11229	73	15	osteomyelitis	osteomyelitis	NOUN
hls-11229	73	16	and	and	CCONJ
hls-11229	73	17	septic	septic	ADJ
hls-11229	73	18	arthritis	arthritis	NOUN
hls-11229	73	19	.	.	PUNCT
hls-11229	74	1	though	though	SCONJ
hls-11229	74	2	clindamycin	clindamycin	NOUN
hls-11229	74	3	has	have	VERB
hls-11229	74	4	several	several	ADJ
hls-11229	74	5	properties	property	NOUN
hls-11229	74	6	to	to	ADP
hls-11229	74	7	its	its	PRON
hls-11229	74	8	advantage	advantage	NOUN
hls-11229	74	9	,	,	PUNCT
hls-11229	74	10	there	there	PRON
hls-11229	74	11	are	be	VERB
hls-11229	74	12	a	a	DET
hls-11229	74	13	few	few	ADJ
hls-11229	74	14	challenges	challenge	NOUN
hls-11229	74	15	that	that	PRON
hls-11229	74	16	a	a	DET
hls-11229	74	17	clinician	clinician	NOUN
hls-11229	74	18	faces	face	NOUN
hls-11229	74	19	while	while	SCONJ
hls-11229	74	20	using	use	VERB
hls-11229	74	21	the	the	DET
hls-11229	74	22	drug	drug	NOUN
hls-11229	74	23	.	.	PUNCT
hls-11229	75	1	pseudomembranous	pseudomembranous	ADJ
hls-11229	75	2	colitis	colitis	NOUN
hls-11229	75	3	due	due	ADP
hls-11229	75	4	to	to	ADP
hls-11229	75	5	clostridioides	clostridioide	NOUN
hls-11229	75	6	difficile	difficile	NOUN
hls-11229	75	7	is	be	AUX
hls-11229	75	8	observed	observe	VERB
hls-11229	75	9	in	in	ADP
hls-11229	75	10	0.110	0.110	NUM
hls-11229	75	11	%	%	NOUN
hls-11229	75	12	of	of	ADP
hls-11229	75	13	the	the	DET
hls-11229	75	14	patients	patient	NOUN
hls-11229	75	15	using	use	VERB
hls-11229	75	16	clindamycin	clindamycin	NOUN
hls-11229	75	17	persistently1	persistently1	ADJ
hls-11229	75	18	and	and	CCONJ
hls-11229	75	19	likelihood	likelihood	NOUN
hls-11229	75	20	of	of	ADP
hls-11229	75	21	failure	failure	NOUN
hls-11229	75	22	if	if	SCONJ
hls-11229	75	23	the	the	DET
hls-11229	75	24	strain	strain	NOUN
hls-11229	75	25	possesses	possess	VERB
hls-11229	75	26	erm	erm	PROPN
hls-11229	75	27	gene	gene	PROPN
hls-11229	75	28	are	be	AUX
hls-11229	75	29	the	the	DET
hls-11229	75	30	two	two	NUM
hls-11229	75	31	main	main	ADJ
hls-11229	75	32	disadvantage	disadvantage	NOUN
hls-11229	75	33	to	to	ADP
hls-11229	75	34	clindamycin	clindamycin	NOUN
hls-11229	75	35	use	use	NOUN
hls-11229	75	36	.	.	PUNCT
hls-11229	76	1	clindamycin	clindamycin	NOUN
hls-11229	76	2	resistance	resistance	NOUN
hls-11229	76	3	can	can	AUX
hls-11229	76	4	either	either	CCONJ
hls-11229	76	5	be	be	AUX
hls-11229	76	6	induced	induce	VERB
hls-11229	76	7	or	or	CCONJ
hls-11229	76	8	can	can	AUX
hls-11229	76	9	be	be	AUX
hls-11229	76	10	rendered	render	VERB
hls-11229	76	11	constitutively	constitutively	ADV
hls-11229	76	12	based	base	VERB
hls-11229	76	13	on	on	ADP
hls-11229	76	14	the	the	DET
hls-11229	76	15	phenotype	phenotype	NOUN
hls-11229	76	16	.	.	PUNCT
hls-11229	77	1	in	in	ADP
hls-11229	77	2	our	our	PRON
hls-11229	77	3	study	study	NOUN
hls-11229	77	4	,	,	PUNCT
hls-11229	77	5	constitutive	constitutive	ADJ
hls-11229	77	6	resistance	resistance	NOUN
hls-11229	77	7	to	to	ADP
hls-11229	77	8	the	the	DET
hls-11229	77	9	mlsb	mlsb	NOUN
hls-11229	77	10	drugs	drug	NOUN
hls-11229	77	11	was	be	AUX
hls-11229	77	12	found	find	VERB
hls-11229	77	13	to	to	PART
hls-11229	77	14	be	be	AUX
hls-11229	77	15	more	more	ADJ
hls-11229	77	16	(	(	PUNCT
hls-11229	77	17	19.3	19.3	NUM
hls-11229	77	18	%	%	NOUN
hls-11229	77	19	)	)	PUNCT
hls-11229	77	20	in	in	ADP
hls-11229	77	21	comparison	comparison	NOUN
hls-11229	77	22	to	to	ADP
hls-11229	77	23	the	the	DET
hls-11229	77	24	inducible	inducible	ADJ
hls-11229	77	25	phenotype	phenotype	NOUN
hls-11229	77	26	.	.	PUNCT
hls-11229	78	1	icr	icr	PROPN
hls-11229	78	2	rates	rate	NOUN
hls-11229	78	3	were	be	AUX
hls-11229	78	4	found	find	VERB
hls-11229	78	5	to	to	PART
hls-11229	78	6	be	be	AUX
hls-11229	78	7	16.35	16.35	NUM
hls-11229	78	8	%	%	NOUN
hls-11229	78	9	,	,	PUNCT
hls-11229	78	10	which	which	PRON
hls-11229	78	11	were	be	AUX
hls-11229	78	12	considerably	considerably	ADV
hls-11229	78	13	higher	high	ADJ
hls-11229	78	14	in	in	ADP
hls-11229	78	15	mrsa	mrsa	NOUN
hls-11229	78	16	isolates	isolate	NOUN
hls-11229	78	17	(	(	PUNCT
hls-11229	78	18	70.8	70.8	NUM
hls-11229	78	19	%	%	NOUN
hls-11229	78	20	)	)	PUNCT
hls-11229	78	21	than	than	ADP
hls-11229	78	22	the	the	DET
hls-11229	78	23	mssa	mssa	ADJ
hls-11229	78	24	strains	strain	NOUN
hls-11229	78	25	.	.	PUNCT
hls-11229	79	1	not	not	PART
hls-11229	79	2	many	many	ADJ
hls-11229	79	3	studies	study	NOUN
hls-11229	79	4	have	have	AUX
hls-11229	79	5	commented	comment	VERB
hls-11229	79	6	upon	upon	SCONJ
hls-11229	79	7	the	the	DET
hls-11229	79	8	reason	reason	NOUN
hls-11229	79	9	justifying	justify	VERB
hls-11229	79	10	the	the	DET
hls-11229	79	11	higher	high	ADJ
hls-11229	79	12	prevalence	prevalence	NOUN
hls-11229	79	13	of	of	ADP
hls-11229	79	14	icr	icr	PROPN
hls-11229	79	15	in	in	ADP
hls-11229	79	16	mrsa	mrsa	NOUN
hls-11229	79	17	,	,	PUNCT
hls-11229	79	18	but	but	CCONJ
hls-11229	79	19	one	one	NUM
hls-11229	79	20	possible	possible	ADJ
hls-11229	79	21	explanation	explanation	NOUN
hls-11229	79	22	is	be	AUX
hls-11229	79	23	more	more	ADJ
hls-11229	79	24	positivity	positivity	NOUN
hls-11229	79	25	rate	rate	NOUN
hls-11229	79	26	for	for	ADP
hls-11229	79	27	erma	erma	NOUN
hls-11229	79	28	in	in	ADP
hls-11229	79	29	mrsa	mrsa	NOUN
hls-11229	79	30	than	than	ADP
hls-11229	79	31	mssa.8	mssa.8	NOUN
hls-11229	79	32	this	this	PRON
hls-11229	79	33	is	be	AUX
hls-11229	79	34	indicative	indicative	ADJ
hls-11229	79	35	of	of	ADP
hls-11229	79	36	increased	increase	VERB
hls-11229	79	37	chances	chance	NOUN
hls-11229	79	38	of	of	ADP
hls-11229	79	39	treatment	treatment	NOUN
hls-11229	79	40	failure	failure	NOUN
hls-11229	79	41	with	with	ADP
hls-11229	79	42	clindamycin	clindamycin	NOUN
hls-11229	79	43	in	in	ADP
hls-11229	79	44	resistant	resistant	ADJ
hls-11229	79	45	infections	infection	NOUN
hls-11229	79	46	.	.	PUNCT
hls-11229	80	1	table	table	NOUN
hls-11229	80	2	4	4	NUM
hls-11229	80	3	compares	compare	VERB
hls-11229	80	4	the	the	DET
hls-11229	80	5	distribution	distribution	NOUN
hls-11229	80	6	of	of	ADP
hls-11229	80	7	mlsb	mlsb	NOUN
hls-11229	80	8	phenotypes	phenotype	NOUN
hls-11229	80	9	in	in	ADP
hls-11229	80	10	various	various	ADJ
hls-11229	80	11	geographical	geographical	ADJ
hls-11229	80	12	regions	region	NOUN
hls-11229	80	13	of	of	ADP
hls-11229	80	14	our	our	PRON
hls-11229	80	15	country	country	NOUN
hls-11229	80	16	and	and	CCONJ
hls-11229	80	17	beyond	beyond	ADP
hls-11229	80	18	.	.	PUNCT
hls-11229	81	1	the	the	DET
hls-11229	81	2	presence	presence	NOUN
hls-11229	81	3	of	of	ADP
hls-11229	81	4	msb	msb	PROPN
hls-11229	81	5	phenotype	phenotype	NOUN
hls-11229	81	6	in	in	ADP
hls-11229	81	7	our	our	PRON
hls-11229	81	8	study	study	NOUN
hls-11229	81	9	was	be	AUX
hls-11229	81	10	higher	high	ADJ
hls-11229	81	11	in	in	ADP
hls-11229	81	12	comparison	comparison	NOUN
hls-11229	81	13	to	to	ADP
hls-11229	81	14	the	the	DET
hls-11229	81	15	other	other	ADJ
hls-11229	81	16	two	two	NUM
hls-11229	81	17	variants	variant	NOUN
hls-11229	81	18	.	.	PUNCT
hls-11229	82	1	similar	similar	ADJ
hls-11229	82	2	finding	finding	NOUN
hls-11229	82	3	was	be	AUX
hls-11229	82	4	observed	observe	VERB
hls-11229	82	5	in	in	ADP
hls-11229	82	6	the	the	DET
hls-11229	82	7	other	other	ADJ
hls-11229	82	8	areas	area	NOUN
hls-11229	82	9	of	of	ADP
hls-11229	82	10	delhi.10	delhi.10	ADJ
hls-11229	82	11	therefore	therefore	ADV
hls-11229	82	12	,	,	PUNCT
hls-11229	82	13	clindamycin	clindamycin	NOUN
hls-11229	82	14	can	can	AUX
hls-11229	82	15	be	be	AUX
hls-11229	82	16	used	use	VERB
hls-11229	82	17	empirically	empirically	ADV
hls-11229	82	18	by	by	ADP
hls-11229	82	19	clinicians	clinician	NOUN
hls-11229	82	20	for	for	ADP
hls-11229	82	21	indicated	indicate	VERB
hls-11229	82	22	infections	infection	NOUN
hls-11229	82	23	with	with	ADP
hls-11229	82	24	lesser	less	ADJ
hls-11229	82	25	chances	chance	NOUN
hls-11229	82	26	of	of	ADP
hls-11229	82	27	it	it	PRON
hls-11229	82	28	turning	turn	VERB
hls-11229	82	29	out	out	ADP
hls-11229	82	30	to	to	PART
hls-11229	82	31	be	be	AUX
hls-11229	82	32	ineffective	ineffective	ADJ
hls-11229	82	33	.	.	PUNCT
hls-11229	83	1	table	table	NOUN
hls-11229	83	2	4	4	NUM
hls-11229	83	3	shows	show	VERB
hls-11229	83	4	the	the	DET
hls-11229	83	5	geographical	geographical	ADJ
hls-11229	83	6	distribution	distribution	NOUN
hls-11229	83	7	of	of	ADP
hls-11229	83	8	mlsb	mlsb	NOUN
hls-11229	83	9	phenotypes	phenotype	NOUN
hls-11229	83	10	in	in	ADP
hls-11229	83	11	various	various	ADJ
hls-11229	83	12	geographical	geographical	ADJ
hls-11229	83	13	regions	region	NOUN
hls-11229	83	14	.	.	PUNCT
hls-11229	84	1	in	in	ADP
hls-11229	84	2	our	our	PRON
hls-11229	84	3	study	study	NOUN
hls-11229	84	4	higher	high	ADJ
hls-11229	84	5	prevalence	prevalence	NOUN
hls-11229	84	6	of	of	ADP
hls-11229	84	7	cmlsb	cmlsb	NOUN
hls-11229	84	8	than	than	ADP
hls-11229	84	9	that	that	PRON
hls-11229	84	10	of	of	ADP
hls-11229	84	11	imlsb	imlsb	NOUN
hls-11229	84	12	was	be	AUX
hls-11229	84	13	observed	observe	VERB
hls-11229	84	14	,	,	PUNCT
hls-11229	84	15	which	which	PRON
hls-11229	84	16	was	be	AUX
hls-11229	84	17	found	find	VERB
hls-11229	84	18	to	to	PART
hls-11229	84	19	be	be	AUX
hls-11229	84	20	in	in	ADP
hls-11229	84	21	concordance	concordance	NOUN
hls-11229	84	22	with	with	ADP
hls-11229	84	23	other	other	ADJ
hls-11229	84	24	studies	study	NOUN
hls-11229	84	25	conducted	conduct	VERB
hls-11229	84	26	in	in	ADP
hls-11229	84	27	the	the	DET
hls-11229	84	28	regions	region	NOUN
hls-11229	84	29	of	of	ADP
hls-11229	84	30	kolkata	kolkata	PROPN
hls-11229	84	31	,	,	PUNCT
hls-11229	84	32	shimla	shimla	NOUN
hls-11229	84	33	and	and	CCONJ
hls-11229	84	34	nepal.4,6,7	nepal.4,6,7	NOUN
hls-11229	84	35	conversely	conversely	ADV
hls-11229	84	36	higher	high	ADJ
hls-11229	84	37	prevalence	prevalence	NOUN
hls-11229	84	38	of	of	ADP
hls-11229	84	39	imlsb	imlsb	NOUN
hls-11229	84	40	than	than	SCONJ
hls-11229	84	41	cmlsb	cmlsb	NOUN
hls-11229	84	42	was	be	AUX
hls-11229	84	43	observed	observe	VERB
hls-11229	84	44	in	in	ADP
hls-11229	84	45	other	other	ADJ
hls-11229	84	46	regions	region	NOUN
hls-11229	84	47	of	of	ADP
hls-11229	84	48	delhi	delhi	PROPN
hls-11229	84	49	and	and	CCONJ
hls-11229	84	50	wardha.5,8	wardha.5,8	PRON
hls-11229	84	51	the	the	DET
hls-11229	84	52	varying	vary	VERB
hls-11229	84	53	article	article	NOUN
hls-11229	84	54	table	table	NOUN
hls-11229	85	1	4	4	NUM
hls-11229	85	2	.	.	PUNCT
hls-11229	85	3	geographical	geographical	ADJ
hls-11229	85	4	distribution	distribution	NOUN
hls-11229	85	5	of	of	ADP
hls-11229	85	6	mlsb	mlsb	NOUN
hls-11229	85	7	phenotypes	phenotype	NOUN
hls-11229	85	8	in	in	ADP
hls-11229	85	9	various	various	ADJ
hls-11229	85	10	geographical	geographical	ADJ
hls-11229	85	11	regions	region	NOUN
hls-11229	85	12	.	.	PUNCT
hls-11229	86	1	study	study	NOUN
hls-11229	86	2	year	year	NOUN
hls-11229	86	3	region	region	NOUN
hls-11229	86	4	no	no	INTJ
hls-11229	86	5	.	.	PROPN
hls-11229	86	6	of	of	ADP
hls-11229	86	7	isolates	isolate	NOUN
hls-11229	86	8	(	(	PUNCT
hls-11229	86	9	n	n	CCONJ
hls-11229	86	10	)	)	PUNCT
hls-11229	86	11	imlsb	imlsb	NOUN
hls-11229	86	12	(	(	PUNCT
hls-11229	86	13	%	%	INTJ
hls-11229	86	14	)	)	PUNCT
hls-11229	86	15	cmlsb	cmlsb	PROPN
hls-11229	86	16	(	(	PUNCT
hls-11229	86	17	%	%	INTJ
hls-11229	86	18	)	)	PUNCT
hls-11229	86	19	msb	msb	PROPN
hls-11229	86	20	(	(	PUNCT
hls-11229	86	21	%	%	INTJ
hls-11229	86	22	)	)	PUNCT
hls-11229	86	23	kumar	kumar	PROPN
hls-11229	86	24	et	et	PROPN
hls-11229	86	25	al.9	al.9	PROPN
hls-11229	86	26	2010	2010	NUM
hls-11229	86	27	kolkata	kolkata	PROPN
hls-11229	86	28	,	,	PUNCT
hls-11229	86	29	india	india	PROPN
hls-11229	86	30	195	195	NUM
hls-11229	86	31	16.9	16.9	NUM
hls-11229	86	32	23.1	23.1	NUM
hls-11229	86	33	16.9	16.9	NUM
hls-11229	86	34	lall	lall	PROPN
hls-11229	86	35	and	and	CCONJ
hls-11229	86	36	sahni	sahni	PROPN
hls-11229	86	37	et	et	PROPN
hls-11229	87	1	al.10	al.10	ADJ
hls-11229	87	2	2014	2014	NUM
hls-11229	87	3	delhi	delhi	PROPN
hls-11229	87	4	,	,	PUNCT
hls-11229	87	5	india	india	PROPN
hls-11229	87	6	305	305	NUM
hls-11229	87	7	43.1	43.1	NUM
hls-11229	87	8	21.4	21.4	NUM
hls-11229	87	9	54.3	54.3	NUM
hls-11229	87	10	mokta	mokta	NOUN
hls-11229	87	11	et	et	NOUN
hls-11229	87	12	al.11	al.11	ADJ
hls-11229	87	13	2015	2015	NUM
hls-11229	87	14	shimla	shimla	NOUN
hls-11229	87	15	,	,	PUNCT
hls-11229	87	16	india	india	PROPN
hls-11229	87	17	350	350	NUM
hls-11229	87	18	13.71	13.71	NUM
hls-11229	87	19	17.14	17.14	NUM
hls-11229	87	20	8.28	8.28	NUM
hls-11229	87	21	deotale	deotale	NOUN
hls-11229	87	22	et	et	PROPN
hls-11229	87	23	al.12	al.12	VERB
hls-11229	87	24	2017	2017	NUM
hls-11229	87	25	wardha	wardha	NOUN
hls-11229	87	26	,	,	PUNCT
hls-11229	87	27	india	india	PROPN
hls-11229	87	28	247	247	NUM
hls-11229	87	29	14.5	14.5	NUM
hls-11229	87	30	3.6	3.6	NUM
hls-11229	87	31	14.17	14.17	NUM
hls-11229	87	32	adhikari	adhikari	PROPN
hls-11229	87	33	et	et	PROPN
hls-11229	87	34	al.13	al.13	PROPN
hls-11229	87	35	2017	2017	NUM
hls-11229	87	36	nepal	nepal	ADJ
hls-11229	87	37	147	147	NUM
hls-11229	87	38	21	21	NUM
hls-11229	87	39	53.4	53.4	NUM
hls-11229	87	40	25.17	25.17	NUM
hls-11229	87	41	our	our	PRON
hls-11229	87	42	study	study	NOUN
hls-11229	87	43	2022	2022	NUM
hls-11229	87	44	east	east	PROPN
hls-11229	87	45	delhi	delhi	PROPN
hls-11229	87	46	,	,	PUNCT
hls-11229	87	47	india	india	PROPN
hls-11229	87	48	752	752	NUM
hls-11229	87	49	16.35	16.35	NUM
hls-11229	87	50	19.28	19.28	NUM
hls-11229	87	51	43.08	43.08	NUM
hls-11229	87	52	figure	figure	NOUN
hls-11229	87	53	2	2	NUM
hls-11229	87	54	.	.	PUNCT
hls-11229	87	55	distribution	distribution	NOUN
hls-11229	87	56	of	of	ADP
hls-11229	87	57	mssa	mssa	NOUN
hls-11229	87	58	and	and	CCONJ
hls-11229	87	59	mrsa	mrsa	NOUN
hls-11229	87	60	among	among	ADP
hls-11229	87	61	staphylococcus	staphylococcus	NOUN
hls-11229	87	62	aureus	aureus	NOUN
hls-11229	87	63	isolates	isolate	NOUN
hls-11229	87	64	exhibiting	exhibit	VERB
hls-11229	87	65	inducible	inducible	ADJ
hls-11229	87	66	clindamycin	clindamycin	NOUN
hls-11229	87	67	resistance	resistance	NOUN
hls-11229	87	68	(	(	PUNCT
hls-11229	87	69	n=752	n=752	NUM
hls-11229	87	70	)	)	PUNCT
hls-11229	87	71	.	.	PUNCT
hls-11229	88	1	table	table	NOUN
hls-11229	88	2	3	3	NUM
hls-11229	88	3	.	.	X
hls-11229	88	4	mssa	mssa	PROPN
hls-11229	88	5	&	&	CCONJ
hls-11229	88	6	mrsa	mrsa	NOUN
hls-11229	88	7	distribution	distribution	NOUN
hls-11229	88	8	amongst	amongst	ADP
hls-11229	88	9	the	the	DET
hls-11229	88	10	constitutive	constitutive	NOUN
hls-11229	88	11	and	and	CCONJ
hls-11229	88	12	msb	msb	PROPN
hls-11229	88	13	phenotypes	phenotype	NOUN
hls-11229	88	14	.	.	PUNCT
hls-11229	89	1	mlsb	mlsb	PROPN
hls-11229	89	2	phenotype	phenotype	NOUN
hls-11229	89	3	mssa	mssa	NOUN
hls-11229	89	4	(	(	PUNCT
hls-11229	89	5	%	%	INTJ
hls-11229	89	6	)	)	PUNCT
hls-11229	89	7	mrsa	mrsa	NOUN
hls-11229	89	8	(	(	PUNCT
hls-11229	89	9	%	%	NOUN
hls-11229	89	10	)	)	PUNCT
hls-11229	89	11	constitutive	constitutive	ADJ
hls-11229	89	12	59	59	NUM
hls-11229	89	13	(	(	PUNCT
hls-11229	89	14	40.7	40.7	NUM
hls-11229	89	15	)	)	PUNCT
hls-11229	89	16	86	86	NUM
hls-11229	89	17	(	(	PUNCT
hls-11229	89	18	59.4	59.4	NUM
hls-11229	89	19	)	)	PUNCT
hls-11229	89	20	msb	msb	PROPN
hls-11229	89	21	171	171	NUM
hls-11229	89	22	(	(	PUNCT
hls-11229	89	23	52.8	52.8	NUM
hls-11229	89	24	)	)	PUNCT
hls-11229	89	25	153	153	NUM
hls-11229	89	26	(	(	PUNCT
hls-11229	89	27	47.2	47.2	NUM
hls-11229	89	28	)	)	PUNCT
hls-11229	90	1	[	[	X
hls-11229	90	2	page	page	NOUN
hls-11229	90	3	28	28	NUM
hls-11229	90	4	]	]	PUNCT
hls-11229	91	1	[	[	X
hls-11229	91	2	healthcare	healthcare	NOUN
hls-11229	91	3	in	in	ADP
hls-11229	91	4	low	low	ADJ
hls-11229	91	5	-	-	PUNCT
hls-11229	91	6	resource	resource	NOUN
hls-11229	91	7	settings	setting	NOUN
hls-11229	91	8	2023	2023	NUM
hls-11229	91	9	;	;	PUNCT
hls-11229	91	10	11:11229	11:11229	NUM
hls-11229	91	11	]	]	X
hls-11229	91	12	non	non	ADJ
hls-11229	91	13	-co	-co	PROPN
hls-11229	91	14	mmerc	mmerc	PROPN
hls-11229	91	15	ial	ial	PROPN
hls-11229	91	16	us	us	PROPN
hls-11229	91	17	e	e	NOUN
hls-11229	91	18	o	o	NOUN
hls-11229	91	19	nly	nly	ADV
hls-11229	91	20	[	[	X
hls-11229	91	21	healthcare	healthcare	NOUN
hls-11229	91	22	in	in	ADP
hls-11229	91	23	low	low	ADJ
hls-11229	91	24	-	-	PUNCT
hls-11229	91	25	resource	resource	NOUN
hls-11229	91	26	settings	setting	NOUN
hls-11229	91	27	2023	2023	NUM
hls-11229	91	28	;	;	PUNCT
hls-11229	91	29	11:11229	11:11229	NUM
hls-11229	91	30	]	]	X
hls-11229	92	1	[	[	X
hls-11229	92	2	page	page	NOUN
hls-11229	92	3	29	29	NUM
hls-11229	92	4	]	]	X
hls-11229	92	5	geographical	geographical	ADJ
hls-11229	92	6	prevalence	prevalence	NOUN
hls-11229	92	7	of	of	ADP
hls-11229	92	8	different	different	ADJ
hls-11229	92	9	resistance	resistance	NOUN
hls-11229	92	10	patterns	pattern	NOUN
hls-11229	92	11	emphasizes	emphasize	VERB
hls-11229	92	12	upon	upon	SCONJ
hls-11229	92	13	the	the	DET
hls-11229	92	14	importance	importance	NOUN
hls-11229	92	15	of	of	ADP
hls-11229	92	16	clindamycin	clindamycin	NOUN
hls-11229	92	17	testing	test	VERB
hls-11229	92	18	in	in	ADP
hls-11229	92	19	all	all	DET
hls-11229	92	20	isolates	isolate	NOUN
hls-11229	92	21	.	.	PUNCT
hls-11229	93	1	it	it	PRON
hls-11229	93	2	was	be	AUX
hls-11229	93	3	observed	observe	VERB
hls-11229	93	4	that	that	SCONJ
hls-11229	93	5	the	the	DET
hls-11229	93	6	prevalence	prevalence	NOUN
hls-11229	93	7	of	of	ADP
hls-11229	93	8	clindamycin	clindamycin	NOUN
hls-11229	93	9	resistance	resistance	NOUN
hls-11229	93	10	(	(	PUNCT
hls-11229	93	11	both	both	CCONJ
hls-11229	93	12	cmlsb	cmlsb	NOUN
hls-11229	93	13	and	and	CCONJ
hls-11229	93	14	imlsb	imlsb	NOUN
hls-11229	93	15	)	)	PUNCT
hls-11229	93	16	was	be	AUX
hls-11229	93	17	more	more	ADV
hls-11229	93	18	in	in	ADP
hls-11229	93	19	mrsa	mrsa	NOUN
hls-11229	93	20	isolates	isolate	NOUN
hls-11229	93	21	in	in	ADP
hls-11229	93	22	comparison	comparison	NOUN
hls-11229	93	23	to	to	ADP
hls-11229	93	24	the	the	DET
hls-11229	93	25	mssa	mssa	ADJ
hls-11229	93	26	isolates	isolate	NOUN
hls-11229	93	27	that	that	PRON
hls-11229	93	28	was	be	AUX
hls-11229	93	29	consistent	consistent	ADJ
hls-11229	93	30	with	with	ADP
hls-11229	93	31	the	the	DET
hls-11229	93	32	findings	finding	NOUN
hls-11229	93	33	of	of	ADP
hls-11229	93	34	other	other	ADJ
hls-11229	93	35	studies.11,14,15	studies.11,14,15	ADV
hls-11229	93	36	against	against	ADP
hls-11229	93	37	the	the	DET
hls-11229	93	38	backdrop	backdrop	NOUN
hls-11229	93	39	of	of	ADP
hls-11229	93	40	the	the	DET
hls-11229	93	41	ever	ever	ADV
hls-11229	93	42	-	-	PUNCT
hls-11229	93	43	changing	change	VERB
hls-11229	93	44	staphylococcal	staphylococcal	ADJ
hls-11229	93	45	resistance	resistance	NOUN
hls-11229	93	46	pattern	pattern	NOUN
hls-11229	93	47	,	,	PUNCT
hls-11229	93	48	clindamycin	clindamycin	NOUN
hls-11229	93	49	remains	remain	VERB
hls-11229	93	50	a	a	DET
hls-11229	93	51	viable	viable	ADJ
hls-11229	93	52	therapeutic	therapeutic	ADJ
hls-11229	93	53	alternative	alternative	NOUN
hls-11229	93	54	.	.	PUNCT
hls-11229	94	1	our	our	PRON
hls-11229	94	2	study	study	NOUN
hls-11229	94	3	may	may	AUX
hls-11229	94	4	prove	prove	VERB
hls-11229	94	5	useful	useful	ADJ
hls-11229	94	6	in	in	ADP
hls-11229	94	7	better	well	ADJ
hls-11229	94	8	understanding	understanding	NOUN
hls-11229	94	9	of	of	ADP
hls-11229	94	10	varying	vary	VERB
hls-11229	94	11	distribution	distribution	NOUN
hls-11229	94	12	of	of	ADP
hls-11229	94	13	different	different	ADJ
hls-11229	94	14	mlsb	mlsb	NOUN
hls-11229	94	15	phenotypes	phenotype	NOUN
hls-11229	94	16	of	of	ADP
hls-11229	94	17	s.aureus	s.aureus	PROPN
hls-11229	94	18	in	in	ADP
hls-11229	94	19	recent	recent	ADJ
hls-11229	94	20	times	time	NOUN
hls-11229	94	21	.	.	PUNCT
hls-11229	95	1	variation	variation	NOUN
hls-11229	95	2	of	of	ADP
hls-11229	95	3	clindamycin	clindamycin	NOUN
hls-11229	95	4	drug	drug	NOUN
hls-11229	95	5	resistance	resistance	NOUN
hls-11229	95	6	patterns	pattern	NOUN
hls-11229	95	7	with	with	ADP
hls-11229	95	8	methicillin	methicillin	NOUN
hls-11229	95	9	susceptibility	susceptibility	NOUN
hls-11229	95	10	,	,	PUNCT
hls-11229	95	11	geographic	geographic	ADJ
hls-11229	95	12	area	area	NOUN
hls-11229	95	13	and	and	CCONJ
hls-11229	95	14	even	even	ADV
hls-11229	95	15	intercity16	intercity16	VERB
hls-11229	95	16	differences	difference	NOUN
hls-11229	95	17	make	make	VERB
hls-11229	95	18	icr	icr	PROPN
hls-11229	95	19	testing	testing	NOUN
hls-11229	95	20	imperative	imperative	NOUN
hls-11229	95	21	for	for	ADP
hls-11229	95	22	all	all	DET
hls-11229	95	23	staphylococcal	staphylococcal	ADJ
hls-11229	95	24	isolates	isolate	NOUN
hls-11229	95	25	to	to	PART
hls-11229	95	26	avoid	avoid	VERB
hls-11229	95	27	therapeutic	therapeutic	ADJ
hls-11229	95	28	failure	failure	NOUN
hls-11229	95	29	.	.	PUNCT
hls-11229	96	1	references	reference	NOUN
hls-11229	96	2	1	1	NUM
hls-11229	96	3	.	.	PUNCT
hls-11229	97	1	clindamycin	clindamycin	NOUN
hls-11229	97	2	:	:	PUNCT
hls-11229	97	3	an	an	DET
hls-11229	97	4	overview	overview	NOUN
hls-11229	97	5	uptodate	uptodate	ADJ
hls-11229	97	6	.	.	PUNCT
hls-11229	98	1	accessed	access	VERB
hls-11229	98	2	2023	2023	NUM
hls-11229	98	3	may	may	PROPN
hls-11229	98	4	11	11	NUM
hls-11229	98	5	.	.	PUNCT
hls-11229	99	1	available	available	ADJ
hls-11229	99	2	from	from	ADP
hls-11229	99	3	:	:	PUNCT
hls-11229	99	4	https://www.uptodate.com/contents/clin	https://www.uptodate.com/contents/clin	PROPN
hls-11229	99	5	damycin	damycin	ADJ
hls-11229	99	6	-	-	PUNCT
hls-11229	99	7	an	an	DET
hls-11229	99	8	-	-	PUNCT
hls-11229	99	9	overview?search	overview?search	NOUN
hls-11229	99	10	=	=	NOUN
hls-11229	99	11	clindamycin%20in%20staphylococcal%20i	clindamycin%20in%20staphylococcal%20i	X
hls-11229	99	12	nfections&source	nfections&source	NOUN
hls-11229	99	13	=	=	NOUN
hls-11229	99	14	search_result&select	search_result&select	VERB
hls-11229	99	15	edtitle=3~150&usage_type	edtitle=3~150&usage_type	NOUN
hls-11229	99	16	=	=	SYM
hls-11229	99	17	default&d	default&d	PROPN
hls-11229	99	18	isplay_rank=3#h12	isplay_rank=3#h12	PROPN
hls-11229	99	19	2	2	NUM
hls-11229	99	20	.	.	PUNCT
hls-11229	99	21	alpha	alpha	NOUN
hls-11229	99	22	toxin	toxin	NOUN
hls-11229	99	23	–	–	PUNCT
hls-11229	99	24	an	an	DET
hls-11229	99	25	overview	overview	NOUN
hls-11229	100	1	|	|	ADV
hls-11229	100	2	sciencedirect	sciencedirect	NOUN
hls-11229	100	3	topics	topic	NOUN
hls-11229	100	4	.	.	PUNCT
hls-11229	101	1	accessed	access	VERB
hls-11229	101	2	2023	2023	NUM
hls-11229	101	3	may	may	PROPN
hls-11229	101	4	11	11	NUM
hls-11229	101	5	.	.	PUNCT
hls-11229	102	1	available	available	ADJ
hls-11229	102	2	from	from	ADP
hls-11229	102	3	:	:	PUNCT
hls-11229	102	4	https://www	https://www	PROPN
hls-11229	102	5	.	.	PROPN
hls-11229	102	6	sciencedirect.com/topics/medicine-anddentistry/alpha-toxin	sciencedirect.com/topics/medicine-anddentistry/alpha-toxin	PROPN
hls-11229	102	7	3	3	NUM
hls-11229	102	8	.	.	PUNCT
hls-11229	102	9	morgan	morgan	PROPN
hls-11229	102	10	m.	m.	PROPN
hls-11229	102	11	staphylococcus	staphylococcus	PROPN
hls-11229	102	12	aureus	aureus	PROPN
hls-11229	102	13	,	,	PUNCT
hls-11229	102	14	panton	panton	PROPN
hls-11229	102	15	-	-	PUNCT
hls-11229	102	16	valentine	valentine	PROPN
hls-11229	102	17	leukocidin	leukocidin	ADV
hls-11229	102	18	,	,	PUNCT
hls-11229	102	19	and	and	CCONJ
hls-11229	102	20	necrotising	necrotise	VERB
hls-11229	102	21	pneumonia	pneumonia	NOUN
hls-11229	102	22	.	.	PUNCT
hls-11229	103	1	bmj	bmj	PROPN
hls-11229	103	2	2005	2005	NUM
hls-11229	103	3	;	;	PUNCT
hls-11229	103	4	331:793	331:793	NUM
hls-11229	103	5	-	-	SYM
hls-11229	103	6	4	4	NUM
hls-11229	103	7	.	.	NOUN
hls-11229	103	8	4	4	NUM
hls-11229	103	9	.	.	X
hls-11229	103	10	saribas	saribas	PROPN
hls-11229	104	1	z	z	PROPN
hls-11229	104	2	,	,	PUNCT
hls-11229	104	3	tunckanat	tunckanat	NOUN
hls-11229	104	4	f	f	PROPN
hls-11229	104	5	,	,	PUNCT
hls-11229	104	6	pinar	pinar	PROPN
hls-11229	104	7	a.	a.	PROPN
hls-11229	104	8	prevalence	prevalence	NOUN
hls-11229	104	9	of	of	ADP
hls-11229	104	10	erm	erm	PROPN
hls-11229	104	11	genes	gene	NOUN
hls-11229	104	12	encoding	encode	VERB
hls-11229	104	13	macrolide	macrolide	NOUN
hls-11229	104	14	-	-	PUNCT
hls-11229	104	15	lincosamide	lincosamide	NOUN
hls-11229	104	16	-	-	PUNCT
hls-11229	104	17	streptogramin	streptogramin	NOUN
hls-11229	104	18	(	(	PUNCT
hls-11229	104	19	mls	mls	PROPN
hls-11229	104	20	)	)	PUNCT
hls-11229	104	21	resistance	resistance	NOUN
hls-11229	104	22	among	among	ADP
hls-11229	104	23	clinical	clinical	ADJ
hls-11229	104	24	isolates	isolate	NOUN
hls-11229	104	25	of	of	ADP
hls-11229	104	26	staphylococcus	staphylococcus	NOUN
hls-11229	104	27	aureus	aureus	NOUN
hls-11229	104	28	in	in	ADP
hls-11229	104	29	a	a	DET
hls-11229	104	30	turkish	turkish	ADJ
hls-11229	104	31	university	university	NOUN
hls-11229	104	32	hospital	hospital	NOUN
hls-11229	104	33	.	.	PUNCT
hls-11229	105	1	clin	clin	PROPN
hls-11229	105	2	microbiol	microbiol	PROPN
hls-11229	105	3	infect	infect	VERB
hls-11229	105	4	2006;12:797	2006;12:797	NOUN
hls-11229	105	5	-	-	SYM
hls-11229	105	6	9	9	NUM
hls-11229	105	7	.	.	NOUN
hls-11229	105	8	5	5	NUM
hls-11229	105	9	.	.	X
hls-11229	106	1	ghanbari	ghanbari	PROPN
hls-11229	107	1	f	f	PROPN
hls-11229	107	2	,	,	PUNCT
hls-11229	107	3	ghajavand	ghajavand	PROPN
hls-11229	107	4	h	h	PROPN
hls-11229	107	5	,	,	PUNCT
hls-11229	107	6	havaei	havaei	PROPN
hls-11229	107	7	r	r	NOUN
hls-11229	107	8	,	,	PUNCT
hls-11229	107	9	et	et	PROPN
hls-11229	107	10	al	al	PROPN
hls-11229	107	11	.	.	PUNCT
hls-11229	108	1	distribution	distribution	NOUN
hls-11229	108	2	of	of	ADP
hls-11229	108	3	erm	erm	PROPN
hls-11229	108	4	genes	gene	NOUN
hls-11229	108	5	among	among	ADP
hls-11229	108	6	staphylococcus	staphylococcus	NOUN
hls-11229	108	7	aureus	aureus	NOUN
hls-11229	108	8	isolates	isolate	NOUN
hls-11229	108	9	with	with	ADP
hls-11229	108	10	inducible	inducible	ADJ
hls-11229	108	11	resistance	resistance	NOUN
hls-11229	108	12	to	to	ADP
hls-11229	108	13	clindamycin	clindamycin	NOUN
hls-11229	108	14	in	in	ADP
hls-11229	108	15	isfahan	isfahan	NOUN
hls-11229	108	16	,	,	PUNCT
hls-11229	108	17	iran	iran	PROPN
hls-11229	108	18	.	.	PUNCT
hls-11229	109	1	adv	adv	PROPN
hls-11229	109	2	biomed	biome	VERB
hls-11229	109	3	res	re	NOUN
hls-11229	109	4	2016;5:62	2016;5:62	NOUN
hls-11229	109	5	.	.	PUNCT
hls-11229	110	1	6	6	NUM
hls-11229	110	2	.	.	X
hls-11229	111	1	clsi-31-2021.pdf	clsi-31-2021.pdf	PROPN
hls-11229	111	2	.	.	PROPN
hls-11229	112	1	accessed	access	VERB
hls-11229	112	2	2022	2022	NUM
hls-11229	112	3	oct	oct	NOUN
hls-11229	112	4	9	9	NUM
hls-11229	112	5	.	.	PUNCT
hls-11229	112	6	available	available	ADJ
hls-11229	112	7	from	from	ADP
hls-11229	112	8	:	:	PUNCT
hls-11229	112	9	https://www.treata	https://www.treata	PROPN
hls-11229	112	10	.	.	PUNCT
hls-11229	112	11	academy	academy	PROPN
hls-11229	112	12	/	/	SYM
hls-11229	112	13	wp	wp	PROPN
hls-11229	112	14	-	-	PUNCT
hls-11229	112	15	content	content	NOUN
hls-11229	112	16	/	/	SYM
hls-11229	112	17	uploads/2021/	uploads/2021/	PROPN
hls-11229	112	18	03	03	NUM
hls-11229	112	19	/	/	SYM
hls-11229	112	20	clsi-31	clsi-31	NOUN
hls-11229	112	21	-	-	PUNCT
hls-11229	112	22	2021.pdf	2021.pdf	NUM
hls-11229	112	23	7	7	NUM
hls-11229	112	24	.	.	PUNCT
hls-11229	113	1	moellering	moellering	PROPN
hls-11229	113	2	,	,	PUNCT
hls-11229	113	3	jr	jr	PROPN
hls-11229	113	4	.	.	PROPN
hls-11229	113	5	rc	rc	PROPN
hls-11229	113	6	.	.	PUNCT
hls-11229	114	1	current	current	ADJ
hls-11229	114	2	treatment	treatment	NOUN
hls-11229	114	3	options	option	NOUN
hls-11229	114	4	for	for	ADP
hls-11229	114	5	community	community	NOUN
hls-11229	114	6	-	-	PUNCT
hls-11229	114	7	acquired	acquire	VERB
hls-11229	114	8	methicillin	methicillin	NOUN
hls-11229	114	9	-	-	PUNCT
hls-11229	114	10	resistant	resistant	ADJ
hls-11229	114	11	staphylococcus	staphylococcus	NOUN
hls-11229	114	12	aureus	aureus	NOUN
hls-11229	114	13	infection	infection	NOUN
hls-11229	114	14	.	.	PUNCT
hls-11229	115	1	clin	clin	PROPN
hls-11229	115	2	infect	infect	PROPN
hls-11229	115	3	dis	dis	PROPN
hls-11229	115	4	2008;46	2008;46	NUM
hls-11229	115	5	:	:	PUNCT
hls-11229	115	6	1032	1032	NUM
hls-11229	115	7	-	-	SYM
hls-11229	115	8	7	7	NUM
hls-11229	115	9	.	.	NOUN
hls-11229	115	10	8	8	NUM
hls-11229	115	11	.	.	PUNCT
hls-11229	116	1	nahar	nahar	PROPN
hls-11229	116	2	l	l	PROPN
hls-11229	116	3	,	,	PUNCT
hls-11229	116	4	hagiya	hagiya	PROPN
hls-11229	116	5	h	h	PROPN
hls-11229	116	6	,	,	PUNCT
hls-11229	116	7	nada	nada	PROPN
hls-11229	116	8	t	t	PROPN
hls-11229	116	9	,	,	PUNCT
hls-11229	116	10	et	et	PROPN
hls-11229	116	11	al	al	PROPN
hls-11229	116	12	.	.	PUNCT
hls-11229	117	1	prevalence	prevalence	NOUN
hls-11229	117	2	of	of	ADP
hls-11229	117	3	inducible	inducible	ADJ
hls-11229	117	4	macrolide	macrolide	NOUN
hls-11229	117	5	,	,	PUNCT
hls-11229	117	6	lincosamide	lincosamide	NOUN
hls-11229	117	7	,	,	PUNCT
hls-11229	117	8	and	and	CCONJ
hls-11229	117	9	streptogramin	streptogramin	PROPN
hls-11229	117	10	b	b	SYM
hls-11229	117	11	(	(	PUNCT
hls-11229	117	12	inducible	inducible	ADJ
hls-11229	117	13	mlsb	mlsb	NOUN
hls-11229	117	14	)	)	PUNCT
hls-11229	117	15	resistance	resistance	NOUN
hls-11229	117	16	in	in	ADP
hls-11229	117	17	clindamycin	clindamycin	NOUN
hls-11229	117	18	-	-	PUNCT
hls-11229	117	19	susceptible	susceptible	ADJ
hls-11229	117	20	staphylococcus	staphylococcus	NOUN
hls-11229	117	21	aureus	aureus	NOUN
hls-11229	117	22	at	at	ADP
hls-11229	117	23	okayama	okayama	PROPN
hls-11229	117	24	university	university	NOUN
hls-11229	117	25	hospital	hospital	NOUN
hls-11229	117	26	.	.	PUNCT
hls-11229	118	1	acta	acta	PROPN
hls-11229	118	2	med	med	PROPN
hls-11229	118	3	okayama	okayama	PROPN
hls-11229	118	4	2023;77	2023;77	NUM
hls-11229	118	5	.	.	PUNCT
hls-11229	119	1	9	9	NUM
hls-11229	119	2	.	.	X
hls-11229	120	1	kumar	kumar	PROPN
hls-11229	120	2	s	s	PROPN
hls-11229	120	3	,	,	PUNCT
hls-11229	120	4	bandyopadhyay	bandyopadhyay	PROPN
hls-11229	120	5	m	m	PROPN
hls-11229	120	6	,	,	PUNCT
hls-11229	120	7	bhattacharya	bhattacharya	PROPN
hls-11229	120	8	k	k	PROPN
hls-11229	120	9	,	,	PUNCT
hls-11229	120	10	et	et	PROPN
hls-11229	120	11	al	al	PROPN
hls-11229	120	12	.	.	PROPN
hls-11229	120	13	inducible	inducible	ADJ
hls-11229	120	14	clindamycin	clindamycin	NOUN
hls-11229	120	15	resistance	resistance	NOUN
hls-11229	120	16	in	in	ADP
hls-11229	120	17	staphylococcus	staphylococcus	NOUN
hls-11229	120	18	isolates	isolate	NOUN
hls-11229	120	19	from	from	ADP
hls-11229	120	20	a	a	DET
hls-11229	120	21	tertiary	tertiary	ADJ
hls-11229	120	22	care	care	NOUN
hls-11229	120	23	hospital	hospital	NOUN
hls-11229	120	24	in	in	ADP
hls-11229	120	25	eastern	eastern	PROPN
hls-11229	120	26	india	india	PROPN
hls-11229	120	27	.	.	PUNCT
hls-11229	121	1	ann	ann	PROPN
hls-11229	121	2	trop	trop	PROPN
hls-11229	121	3	med	med	PROPN
hls-11229	121	4	public	public	ADJ
hls-11229	121	5	health	health	PROPN
hls-11229	121	6	2012;5:468	2012;5:468	PROPN
hls-11229	121	7	.	.	PROPN
hls-11229	122	1	10	10	NUM
hls-11229	122	2	.	.	PUNCT
hls-11229	123	1	lall	lall	PROPN
hls-11229	123	2	m	m	PROPN
hls-11229	123	3	,	,	PUNCT
hls-11229	123	4	sahni	sahni	PROPN
hls-11229	123	5	ak	ak	PROPN
hls-11229	123	6	.	.	PROPN
hls-11229	123	7	prevalence	prevalence	NOUN
hls-11229	123	8	of	of	ADP
hls-11229	123	9	inducible	inducible	ADJ
hls-11229	123	10	clindamycin	clindamycin	NOUN
hls-11229	123	11	resistance	resistance	NOUN
hls-11229	123	12	in	in	ADP
hls-11229	123	13	staphylococcus	staphylococcus	NOUN
hls-11229	123	14	aureus	aureus	NOUN
hls-11229	123	15	isolated	isolate	VERB
hls-11229	123	16	from	from	ADP
hls-11229	123	17	clinical	clinical	ADJ
hls-11229	123	18	samples	sample	NOUN
hls-11229	123	19	.	.	PUNCT
hls-11229	124	1	med	med	PROPN
hls-11229	124	2	j	j	PROPN
hls-11229	124	3	armed	armed	PROPN
hls-11229	124	4	forces	force	NOUN
hls-11229	124	5	india	india	PROPN
hls-11229	124	6	2014;70:43	2014;70:43	NUM
hls-11229	124	7	-	-	SYM
hls-11229	124	8	7	7	NUM
hls-11229	124	9	.	.	NOUN
hls-11229	124	10	11	11	NUM
hls-11229	124	11	.	.	PUNCT
hls-11229	125	1	mokta	mokta	PROPN
hls-11229	125	2	kk	kk	PROPN
hls-11229	125	3	,	,	PUNCT
hls-11229	125	4	verma	verma	PROPN
hls-11229	125	5	s	s	PROPN
hls-11229	125	6	,	,	PUNCT
hls-11229	125	7	chauhan	chauhan	PROPN
hls-11229	125	8	d	d	PROPN
hls-11229	125	9	,	,	PUNCT
hls-11229	125	10	et	et	PROPN
hls-11229	125	11	al	al	PROPN
hls-11229	125	12	.	.	PROPN
hls-11229	125	13	inducible	inducible	ADJ
hls-11229	125	14	clindamycin	clindamycin	NOUN
hls-11229	125	15	resistance	resistance	NOUN
hls-11229	125	16	among	among	ADP
hls-11229	125	17	clinical	clinical	ADJ
hls-11229	125	18	isolates	isolate	NOUN
hls-11229	125	19	of	of	ADP
hls-11229	125	20	staphylococcus	staphylococcus	NOUN
hls-11229	125	21	aureus	aureus	NOUN
hls-11229	125	22	from	from	ADP
hls-11229	125	23	sub	sub	PROPN
hls-11229	125	24	himalayan	himalayan	ADJ
hls-11229	125	25	region	region	NOUN
hls-11229	125	26	of	of	ADP
hls-11229	125	27	india	india	PROPN
hls-11229	125	28	.	.	PUNCT
hls-11229	126	1	j	j	PROPN
hls-11229	126	2	clin	clin	PROPN
hls-11229	126	3	diagn	diagn	PROPN
hls-11229	126	4	res	res	PROPN
hls-11229	126	5	jcdr	jcdr	PROPN
hls-11229	126	6	2015;9	2015;9	NUM
hls-11229	126	7	:	:	PUNCT
hls-11229	126	8	dc20	dc20	PROPN
hls-11229	126	9	-	-	PUNCT
hls-11229	126	10	3	3	NUM
hls-11229	126	11	.	.	NOUN
hls-11229	126	12	12	12	NUM
hls-11229	126	13	.	.	PUNCT
hls-11229	127	1	deotale	deotale	PROPN
hls-11229	127	2	v	v	PROPN
hls-11229	127	3	,	,	PUNCT
hls-11229	127	4	mendiratta	mendiratta	NOUN
hls-11229	127	5	d	d	PROPN
hls-11229	127	6	,	,	PUNCT
hls-11229	127	7	raut	raut	PROPN
hls-11229	127	8	u	u	PROPN
hls-11229	127	9	,	,	PUNCT
hls-11229	127	10	narang	narang	PROPN
hls-11229	127	11	p.	p.	PROPN
hls-11229	127	12	inducible	inducible	VERB
hls-11229	127	13	clindamycin	clindamycin	NOUN
hls-11229	127	14	resistance	resistance	NOUN
hls-11229	127	15	in	in	ADP
hls-11229	127	16	staphylococcus	staphylococcus	NOUN
hls-11229	127	17	aureus	aureus	NOUN
hls-11229	127	18	isolated	isolate	VERB
hls-11229	127	19	from	from	ADP
hls-11229	127	20	clinical	clinical	ADJ
hls-11229	127	21	samples	sample	NOUN
hls-11229	127	22	.	.	PUNCT
hls-11229	128	1	indian	indian	PROPN
hls-11229	128	2	j	j	PROPN
hls-11229	128	3	med	med	PROPN
hls-11229	128	4	microbiol	microbiol	PROPN
hls-11229	128	5	2010;28:124	2010;28:124	PROPN
hls-11229	128	6	-	-	PUNCT
hls-11229	128	7	6	6	NUM
hls-11229	128	8	.	.	NOUN
hls-11229	128	9	13	13	NUM
hls-11229	128	10	.	.	PUNCT
hls-11229	129	1	adhikari	adhikari	PROPN
hls-11229	129	2	rp	rp	PROPN
hls-11229	129	3	,	,	PUNCT
hls-11229	129	4	shrestha	shrestha	PROPN
hls-11229	129	5	s	s	PROPN
hls-11229	129	6	,	,	PUNCT
hls-11229	129	7	barakoti	barakoti	PROPN
hls-11229	129	8	a	a	PRON
hls-11229	129	9	,	,	PUNCT
hls-11229	129	10	amatya	amatya	PROPN
hls-11229	129	11	r.	r.	PROPN
hls-11229	129	12	inducible	inducible	ADJ
hls-11229	129	13	clindamycin	clindamycin	NOUN
hls-11229	129	14	and	and	CCONJ
hls-11229	129	15	methicillin	methicillin	NOUN
hls-11229	129	16	resistant	resistant	ADJ
hls-11229	129	17	staphylococcus	staphylococcus	NOUN
hls-11229	129	18	aureus	aureus	NOUN
hls-11229	129	19	in	in	ADP
hls-11229	129	20	a	a	DET
hls-11229	129	21	tertiary	tertiary	ADJ
hls-11229	129	22	care	care	NOUN
hls-11229	129	23	hospital	hospital	NOUN
hls-11229	129	24	,	,	PUNCT
hls-11229	129	25	kathmandu	kathmandu	NOUN
hls-11229	129	26	,	,	PUNCT
hls-11229	129	27	nepal	nepal	ADJ
hls-11229	129	28	.	.	PUNCT
hls-11229	130	1	bmc	bmc	PROPN
hls-11229	130	2	infect	infect	PROPN
hls-11229	130	3	dis	dis	PROPN
hls-11229	130	4	2017;17:483	2017;17:483	NUM
hls-11229	130	5	.	.	PUNCT
hls-11229	131	1	14	14	NUM
hls-11229	131	2	.	.	PUNCT
hls-11229	132	1	supriyarajvi	supriyarajvi	VERB
hls-11229	132	2	,	,	PUNCT
hls-11229	132	3	gupta	gupta	PROPN
hls-11229	132	4	a	a	PRON
hls-11229	132	5	,	,	PUNCT
hls-11229	132	6	tina	tina	PROPN
hls-11229	132	7	g	g	PROPN
hls-11229	132	8	,	,	PUNCT
hls-11229	132	9	sharma	sharma	PROPN
hls-11229	132	10	bp	bp	PROPN
hls-11229	132	11	.	.	PUNCT
hls-11229	132	12	detection	detection	NOUN
hls-11229	132	13	of	of	ADP
hls-11229	132	14	inducible	inducible	ADJ
hls-11229	132	15	clindamycin	clindamycin	NOUN
hls-11229	132	16	resistance	resistance	NOUN
hls-11229	132	17	among	among	ADP
hls-11229	132	18	staphylococcal	staphylococcal	ADJ
hls-11229	132	19	isolates	isolate	NOUN
hls-11229	132	20	from	from	ADP
hls-11229	132	21	various	various	ADJ
hls-11229	132	22	clinical	clinical	ADJ
hls-11229	132	23	specimens	specimen	NOUN
hls-11229	132	24	in	in	ADP
hls-11229	132	25	a	a	DET
hls-11229	132	26	tertiary	tertiary	ADJ
hls-11229	132	27	care	care	NOUN
hls-11229	132	28	institute	institute	NOUN
hls-11229	132	29	in	in	ADP
hls-11229	132	30	north	north	PROPN
hls-11229	132	31	west	west	PROPN
hls-11229	132	32	region	region	PROPN
hls-11229	132	33	of	of	ADP
hls-11229	132	34	rajasthan	rajasthan	PROPN
hls-11229	132	35	,	,	PUNCT
hls-11229	132	36	india	india	PROPN
hls-11229	132	37	.	.	PUNCT
hls-11229	133	1	int	int	PROPN
hls-11229	134	1	j	j	PROPN
hls-11229	134	2	curr	curr	PROPN
hls-11229	134	3	microbiol	microbiol	PROPN
hls-11229	134	4	appl	appl	PROPN
hls-11229	134	5	sci	sci	PROPN
hls-11229	134	6	2015;4:741	2015;4:741	PROPN
hls-11229	134	7	-	-	PUNCT
hls-11229	134	8	9	9	NUM
hls-11229	134	9	.	.	NOUN
hls-11229	134	10	15	15	NUM
hls-11229	134	11	.	.	PUNCT
hls-11229	135	1	molecular	molecular	ADJ
hls-11229	135	2	characterisation	characterisation	NOUN
hls-11229	135	3	of	of	ADP
hls-11229	135	4	methicillin	methicillin	NOUN
hls-11229	135	5	-	-	PUNCT
hls-11229	135	6	resistant	resistant	ADJ
hls-11229	135	7	staphylococcus	staphylococcus	NOUN
hls-11229	135	8	aureus	aureus	NOUN
hls-11229	135	9	isolated	isolate	VERB
hls-11229	135	10	from	from	ADP
hls-11229	135	11	patients	patient	NOUN
hls-11229	135	12	at	at	ADP
hls-11229	135	13	a	a	DET
hls-11229	135	14	tertiary	tertiary	ADJ
hls-11229	135	15	care	care	NOUN
hls-11229	135	16	hospital	hospital	NOUN
hls-11229	135	17	in	in	ADP
hls-11229	135	18	hyderabad	hyderabad	PROPN
hls-11229	135	19	,	,	PUNCT
hls-11229	135	20	south	south	PROPN
hls-11229	135	21	india	india	PROPN
hls-11229	135	22	.	.	PUNCT
hls-11229	136	1	indian	indian	PROPN
hls-11229	136	2	j	j	PROPN
hls-11229	136	3	med	med	PROPN
hls-11229	136	4	microbiol	microbiol	PROPN
hls-11229	136	5	2020;38:183	2020;38:183	PROPN
hls-11229	136	6	-	-	SYM
hls-11229	136	7	92	92	NUM
hls-11229	136	8	.	.	PUNCT
hls-11229	136	9	16	16	NUM
hls-11229	136	10	.	.	PUNCT
hls-11229	137	1	schreckenberger	schreckenberger	NOUN
hls-11229	137	2	pc	pc	PROPN
hls-11229	137	3	,	,	PUNCT
hls-11229	137	4	ilendo	ilendo	PROPN
hls-11229	137	5	e	e	PROPN
hls-11229	137	6	,	,	PUNCT
hls-11229	137	7	ristow	ristow	PROPN
hls-11229	137	8	kl	kl	PROPN
hls-11229	137	9	.	.	PUNCT
hls-11229	137	10	incidence	incidence	NOUN
hls-11229	137	11	of	of	ADP
hls-11229	137	12	constitutive	constitutive	ADJ
hls-11229	137	13	and	and	CCONJ
hls-11229	137	14	inducible	inducible	ADJ
hls-11229	137	15	clindamycin	clindamycin	NOUN
hls-11229	137	16	resistance	resistance	NOUN
hls-11229	137	17	in	in	ADP
hls-11229	137	18	staphylococcus	staphylococcus	NOUN
hls-11229	137	19	aureus	aureus	NOUN
hls-11229	137	20	and	and	CCONJ
hls-11229	137	21	coagulasenegative	coagulasenegative	ADJ
hls-11229	137	22	staphylococci	staphylococci	NOUN
hls-11229	137	23	in	in	ADP
hls-11229	137	24	a	a	DET
hls-11229	137	25	community	community	NOUN
hls-11229	137	26	and	and	CCONJ
hls-11229	137	27	a	a	DET
hls-11229	137	28	tertiary	tertiary	ADJ
hls-11229	137	29	care	care	NOUN
hls-11229	137	30	hospital	hospital	NOUN
hls-11229	137	31	.	.	PUNCT
hls-11229	138	1	j	j	PROPN
hls-11229	138	2	clin	clin	PROPN
hls-11229	138	3	microbiol	microbiol	PROPN
hls-11229	138	4	2004;42:2777	2004;42:2777	NUM
hls-11229	138	5	-	-	PUNCT
hls-11229	138	6	9	9	NUM
hls-11229	138	7	.	.	PUNCT
hls-11229	139	1	article	article	NOUN
hls-11229	139	2	non	non	ADJ
hls-11229	139	3	-co	-co	PROPN
hls-11229	139	4	mmerc	mmerc	PROPN
hls-11229	139	5	ial	ial	PROPN
hls-11229	139	6	us	us	PROPN
hls-11229	139	7	e	e	NOUN
hls-11229	139	8	o	o	NOUN
hls-11229	139	9	nly	nly	ADV